Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 1 of 57 
 PROTOCOL  
TITLE:  Letermovir for cytomegalovirus prophylaxis in patients with 
hematological malignancies treated with alemtuzumab  
STUDY  NUMBER:  OSU -19289  
IND NUMBER:  147864  
TEST PRODUCTS:  NA 
COMMERICAL PRODUCTS:  Letermovir  
INDICATION:  Hematologic malignancies treated with alemtuzumab  
INVESTIGATOR:  John C. Reneau, MD, PhD  
320 West 10th Avenue  
A350A Starling Loving Hall   
Telephone: 614 -688-7942  
Fax: 614 -293-7526  
E-mail:  john.reneau@osumc.edu  
Statistician  Ying Huang, MSc  
320 West 10th Avenue  
Telephone: 614 -688-7591  
Fax: 614 -293-7526  
Email: ying.huang@osum c.edu  
SUPPORT PROVIDED  BY: The Ohio  State University   
Merck  
 1 
CONFIDENTIAL  2 
This is an Ohio  State  University  document  that contains  confidential  information.  It is intended  3 
solely  for the recipient  clinical  investigator(s)  and must  not be disclosed  to any other  party.  This 4 
material  may be used  only for evaluating  or conducting  clinical  investigations;  any other  5 
proposed  use requires  written  consent  from Ohio  State  University.  6 
  7 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 2 of 57 
  8 
TABLE OF CONTENTS  9 
Trial Summary ................................ ................................ ................................ ............................  5 10 
1 Background and Rationale  ................................ ................................ ................................ .. 7 11 
1.1 Mature T -cell Lymphomas  ................................ ................................ ............................  7 12 
1.1.1  Peripheral T -cell Lymphoma  ................................ ................................ .................  7 13 
1.1.2  Cutaneous T -cell Lymphoma  ................................ ................................ ................  7 14 
1.1.3  T-cell Prolymphocytic Leukemia  ................................ ................................ ...........  7 15 
1.2 Alemtuzumab  ................................ ................................ ................................ ...............  8 16 
1.3 Cytomegalovirus  ................................ ................................ ................................ ..........  8 17 
1.4 Letermovir  ................................ ................................ ................................ ................... 10 18 
2 Objectives and Endpoints  ................................ ................................ ................................ ..11 19 
2.1 Objectives  ................................ ................................ ................................ ................... 11 20 
2.1.1  Primary  Objective  ................................ ................................ ................................ 11 21 
2.1.2  Secondary Objectives  ................................ ................................ .......................... 11 22 
2.1.3  Exploratory Objectives  ................................ ................................ ......................... 11 23 
2.2 Endpoints  ................................ ................................ ................................ .................... 11 24 
2.2.1  Primary Endpoint  ................................ ................................ ................................ .11 25 
2.2.2  Secondary Endpoints  ................................ ................................ ........................... 11 26 
2.2.3  Exploratory Endpoints  ................................ ................................ .......................... 11 27 
3 Patients and Methods  ................................ ................................ ................................ ........ 11 28 
3.1 Inclusion Criteria  ................................ ................................ ................................ ......... 11 29 
3.2 Exclusion Criteria  ................................ ................................ ................................ ........ 13 30 
3.3 Screening Procedures  ................................ ................................ ................................ 15 31 
4 Treatment Plan  ................................ ................................ ................................ .................. 15 32 
4.1 Premedication Administration  ................................ ................................ ..................... 15 33 
4.2 Agent Administration  ................................ ................................ ................................ ...15 34 
4.3 Rationale for Dose Selection  ................................ ................................ ....................... 15 35 
4.4 Concomitant Medications and Supportive Care  ................................ .......................... 16 36 
5 Toxicities, Dose Delays, and Dose Modifications  ................................ ............................... 17 37 
5.1 Dose Delays and Modifications  ................................ ................................ ................... 17 38 
5.2 Protocol Therapy Discontinuation  ................................ ................................ ............... 17 39 
6 Study Evaluations  ................................ ................................ ................................ .............. 18 40 
6.1 Calendar of Events  ................................ ................................ ................................ .....18 41 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 3 of 57 
 6.2 Biospecimen Studies and Procedures ................................ ................................ ......... 19 42 
6.3 Source and Timing of Biospecimen Collections  ................................ .......................... 19 43 
6.4 Storage of Biospecimens  ................................ ................................ ............................ 19 44 
7 Criteria for Disease Evaluation  ................................ ................................ ........................... 19 45 
8 Letermovir Information  ................................ ................................ ................................ .......19 46 
8.1 Letermovir Description and Mechanism of Action  ................................ ....................... 19 47 
8.2 Clinical Pharmacology  ................................ ................................ ................................ 20 48 
8.3 Pharmacokinetics and Drug Metabolism  ................................ ................................ .....20 49 
8.4 Preparation, Storage, and Administration: Oral Formulation  ................................ .......33 50 
8.5 Preparation, Storage, and Administration: Intravenous formulation  ............................. 34 51 
8.6 Non Clinical Toxicology  ................................ ................................ ............................... 36 52 
8.6.1  Carcinogenesis, Mutagenesis, Impairment of Fertility  ................................ .......... 36 53 
8.6.2  Animal Toxicology and Pharmacology  ................................ ................................ .36 54 
8.7 Clinical Studies  ................................ ................................ ................................ ........... 36 55 
8.8 Adverse Events  ................................ ................................ ................................ ........... 41 56 
9 Regulatory and Reporting Requirements  ................................ ................................ ........... 43 57 
9.1 Adverse Events (AEs)  ................................ ................................ ................................ .43 58 
9.2 Serious Adverse Events (SAEs)  ................................ ................................ .................. 44 59 
9.3 Noncompliance  ................................ ................................ ................................ ........... 44 60 
9.4 Serious Noncompliance  ................................ ................................ .............................. 45 61 
9.5 Reporting to the OSU IRB  ................................ ................................ ........................... 45 62 
9.6 Reporting to the sponsor  ................................ ................................ ............................. 45 63 
9.7 Reporting to the FDA  ................................ ................................ ................................ ..45 64 
9.8 Timeframe for Reporting Required Events  ................................ ................................ ..46 65 
9.9 Overdose  ................................ ................................ ................................ .................... 47 66 
9.10  Pregnancies  ................................ ................................ ................................ ................ 47 67 
9.11  Data and safety monitoring  ................................ ................................ ......................... 47 68 
9.11.1  Data Submission  ................................ ................................ ................................ ..48 69 
9.11.2  Auditing  ................................ ................................ ................................ ................ 48 70 
9.12  Ethical Considerations  ................................ ................................ ................................ 48 71 
9.13  Retention of records  ................................ ................................ ................................ ....48 72 
10 Statistical Methods  ................................ ................................ ................................ ......... 48 73 
10.1  Study Design and Sample Size Justification  ................................ ............................... 48 74 
10.2  Analysis of Primary Objective  ................................ ................................ ..................... 49 75 
10.3  Analysis of Secondary Objectives  ................................ ................................ ............... 49 76 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 4 of 57 
 10.4  Analysis of Exploratory Objectives  ................................ ................................ .............. 50 77 
11 References  ................................ ................................ ................................ ..................... 50 78 
12 Appendices  ................................ ................................ ................................ .................... 54 79 
12.1  CMV Disease Definitions Working Group of the Cytomegalovirus Drug Development 80 
Forum  54 81 
12.2  Eastern Cooperative Oncology Group Performance Status Scale  ............................... 56 82 
12.3  Child -Pugh Classification of liver disease  ................................ ................................ ....57 83 
 84 
  85 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 5 of 57 
 TRIAL SUMMARY  86 
TITLE  Letermovir for cytomegalovirus prophylaxis in patients with 
hematological malignancies treated with alemtuzumab  
PHASE  II 
OBJECTIVES  Primary Objective  
1. To estimate the rate of CMV reactivation in patients treated with 
letermovir at 3 months after completion of alemtuzumab therapy.  
 
Secondary Objectives  
1. To evaluate the tolerability of letermovir in combination with 
alemtuzumab.  
2. To evaluate the ef ficacy of letermovir for the prevention of clinically 
significant CMV disease.  
4. To estimate the overall survival of patients in the study population  
STUDY DESIGN  Single center, single arm, non -randomized  
KEY ELIGIBILITY 
CRITERIA  Inclusion Criteria  
1. Confirmed diagnosis of  any lymphoid malignancy including, but not 
limited to,  T- or B-PLL, CLL, PTCL, CTCL, Sézary syndrome , or 
LGLL . 
2. Intent to treat with alemtuzumab (monotherapy or in combination 
with chemotherapy).  
3. Confirmed seroposit ivity for CMV IgG  
4. Confirmed lack of active CMV infection as evidenced by CMV DNA 
PCR ≤ 200 IU/mL and no clinical evidence of CMV disease  within  14 
days of first letermovir dose.  
5. Age ≥18 years old  
6. Able to provide informed consent   
7. Life expectan cy >4 months  
8. ECOG performance status ≤3  
9. Highly unlikely to become pregnant or impregnate a partner (post -
menopausal, sterile, abstinence, or adequate contraceptive method)  
 
Exclusion Criteria  
1. History of confirmed CMV disease within 1 year of study  entry.  
2. History of prior allogeneic hematopoietic stem cell transplant  within 
6 months of enrollment . Allogeneic transplant more than 6  months 
prior to enrollment is allowed  as long as the subject is off 
immunosuppression without active GVHD . 
3. End st age renal disease with creatinine clearance < 10 mL/min  
4. Severe hepatic impairment defined as Child -Pugh class C OR AST 
or ALT > 5 x ULN OR serum total bilirubin > 2.5 x ULN.  
5. Both moderate hepatic insufficiency AND moderate renal 
insufficiency define d as Child Pugh Class B AND creatinine clearance 
less than 50 mL/min  
6. Cytopenias are NOT an exclusion criteria  
7. Received antiviral medications with activity against CMV or 
contraindicated medication within sp ecified windows (see Section 3.2 
for details)  
8. Received cidofovir, CMV hyper -immune globulin, or an 
investigational anti CMV agent within 30 days.  
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 6 of 57 
 9. Infection or underlying disease necessitating ongoing use of 
prohibited medications (Section 4.4).  
10. Suspected or known hypersensitivity to active or inactive 
ingredients of letermovir formulations  
11. Active HIV, hepatitis B, or hepatitis C infection (see section 3.2 for 
exceptions)  
12. Pregnant, breas tfeeding, or expecting to conceive.  
13. Expecting to donate eggs or sperm  
14. Current or recent participation in a study with an u napproved 
investigational compound.  
15. Previous participation in a study using letermovir.  
16. Any condition which might interfere with subjects participation as 
judged by investigator.  
STATISTICS  The primary objective of this single center, single arm phase II study 
is to determine the efficacy of letermovir prophylaxis in PLL, CLL, 
PTCL or CTCL patients treated with alemtuzumab. The efficacy will 
be measured through the CMV reactivation rate during letermovir 
prophylaxis (3 months after completion of a lemtuzumab therapy). All 
eligible patients who receive any letermovir will be included in the 
tolerability  analysis, and all patients who receive ≥90% of planned 
letermovir doses are evaluable for the efficacy analysis.  
Fleming’s two -stage design will be u sed with the following 
parameters:  
• Null hypothesis: CMV reactivation rate of 30% or higher is not 
acceptable (70% safety rate)  
• Alternative hypothesis: CMV reactivation rate of 10% or less is 
acceptable (90% safety rate)  
With a one -sided type I error rate o f 5% and 85% power, Fleming’s 
two-stage design allows a first -stage analysis after the first 14 
patients are enrolled and evaluated:  
• If ≥4 CMV reactivations , trial will terminate due to futility  
• If 0 CMV reactivations, trial will terminate due to efficacy  
• If 1-3 CMV reactivations, tr ial will accrue an additional 14  
patients.  
o If at least 24 of 28 enrolled patients are CMV free, we 
will conclude the regimen effective  
To account for the possibility that some patients will not be evaluable, 
we will allow a 5% o ver-accrual for a total target enrollment of 30.  
 
TOTAL NUMBER 
OF SUBJECTS  14 to 30 depending upon results of interim analysis.  
ESTIMATED 
ENROLLMENT 
PERIOD  Stage 1: 10 months from first patient enrolled  
Stage 2: 20 months from first patient enrolled  
ESTIMATED STUDY 
DURATION  Stage 1: 17 months from first patient enrolled  
Stage 2: 27 months from first patient enrolled  
 
 87 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 7 of 57 
 1 BACKGROUND AND RATIONALE  88 
1.1 Mature T-cell Lymphomas  89 
Approximately 10 -15% of non -Hodgkin lymphomas (NHL) are derived from mature (i.e . post - 90 
thymic) T lymphocytes  [1]. The heterogeneity of these lymphomas and poor understanding of 91 
their pathogenesis continue to impede their classification and the development of novel 92 
therapeutic strategies.  93 
1.1.1  Peripheral T -cell Lymphoma  94 
The most common subtype of peripheral T-cell lymphoma (PTCL) lacks any distinguishing 95 
characteristics and is designated by the World Health Organization as “PTCL, not oth erwise 96 
specified (PTCL, NOS)” [1, 2] . While the development of combination  immunochemotherapy 97 
(e.g. “R -CHOP”) has led to significant survival benefits in B -cell NHL, the PTCLs are associated 98 
with inferior responses to  therapy and overall survival  [3]. In fact, the vast majority of PTCL 99 
patients will ultimately succumb to thei r disease, most within a few years of diagnosis  [1, 2, 4] . 100 
Novel therapeutic strategies are needed if improved outcomes are to be achieved. The 101 
observation that PTCL incidence rates are increasing faster than almost any other subgroup of 102 
NHL further heigh tens this sense of urgency  [5, 6] . 103 
1.1.2  Cutaneous T -cell Lymphoma  104 
Primary cutaneous T -cell lymphoma (CTCL), of which the two most common forms are mycosis 105 
fungoides (MF) and Sézary syndrome (SS), predominantly involves the skin. Most CTCL 106 
patients pre sent with limited -stage disease that is confined to the skin (i.e. patches or plaques) 107 
and are managed with topical therapies. In contrast, patients with advanced -stage disease with 108 
significant blood, nodal or visceral organ involvement are managed with sy stemic therapies  [7]. 109 
A variety of single agent or combination chemotherapy regimens are utilized, as there is no 110 
standard of care for these patients. Therefore, the National  Comprehensive Cancer Network 111 
(NCCN) guidelines endorse these agents or participation in a clinical trial as first -line therapy in 112 
these patients. Median overall survival for patients with stage IV disease ranges from 1.4 -3.8 113 
years, depending upon the exte nt of blood, nodal or visceral organ involvement  [8]. Five FDA 114 
approved agents are currently available for CTCL patients failing at least one prior therapy, 115 
includ ing bexarotene, vorinostat, romidepsin , brentuximab vedot in (for CD30 positive disease), 116 
and mogamulizumab . These agents are associated with overall response rates of 28-56% [9-15] 117 
with generally short duration of response . Despite the use of these novel agents, the long term 118 
outlook for most CTCL patients remains grim.  119 
1.1.3  T-cell Prolymphocytic Leukemia  120 
T-cell prolymphocyti c leukemia (T -PLL) is a rare  T-cell malignancy most o ften presenting in 121 
adult males [16]. While most presentations of this disease are acute, a minority of patients will 122 
not require treatment immediately. There is a limited response to conventional chemotherapy 123 
with a lkylating agents or anthracyclines, with a m edian overall survival (OS) of 7 months in 124 
historical series  [16, 17] . In the absence of a clinical trials, patients should be offered 125 
alemtuzumab as front line therapy. Alemtuzumab has a high overall response r ate >80% in the 126 
front line setting  [18] and 5 1-76% in the relapsed setting  [19-22]. Even with high response rates, 127 
relapse is common in the absence of consolidative therapy. Allogeneic hematopoietic stem cell 128 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 8 of 57 
 transplantation is frequently recommended as consolidation therapy with resulted prolongation 129 
of overall survival and cure in a minority of cases  [23-26] 130 
1.2 Alemtuzumab  131 
Alemtuzumab is a humanized IgG1 kappa monoclonal antibody directed against the CD52 132 
antigen, which is mostly expressed by B - and T -lymphocytes. Clinical activity of alemtuzumab 133 
has been evaluated in  multiple lymphoid malignancies including  peripheral T cell lymphoma 134 
(PTCL ), mycosis fungoides ( MF), Sézary syndrome (SS), T-cell prolymphocytic leukemia (T - 135 
PLL), and chronic lymphocytic leukemia (CLL) [27].  136 
In the relapsed setting, alemtuzumab monotherapy results in 36% overall response rate (ORR) 137 
with 21% complete response rate (CRR ) in PTCL  [28]. Patients  with MF/SS have an  ORR 138 
ranging  from 55% to 100% with an average ORR of 65% [29]. Patients with e rythrodermic MF or 139 
SS have significantly better responses (ORR 85 -100%) even with lower doses of alemtuzumab 140 
therapy [30, 31] . Alemtuzumab is considered standard front line therapy for symptomatic T -PLL 141 
(NCCN guidelines)  with O RR of 51 -76% and CRR of 40 -60% [21, 22] . Alemtuzumab has also 142 
been used in combination with various chemotherapeutic agents in the front line and relapsed 143 
setting in these diseases  including CHOP (cyclophosphamide, doxorubicin, v incristine, and 144 
prednisone), EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin), 145 
and pentostatin  [32-34]. Efficacy is improved with these combinations, but also  results in 146 
cumulative toxicities .  147 
In general, therapy with alemtuzumab is well tolerated, but cytomegalovirus (CMV) reactivation 148 
and other infectious complications remain a sig nificant barrier to more widespread clinical use. 149 
In clinica l trials where data is available, reported rates of CMV reactivation average 30%  (see 150 
Table 1). 151 
1.3 Cytomegalovirus  152 
Infection with human cytomegalovirus (CMV) is relatively frequent in the human population with 153 
a seroprevalence ranging from 45 -100%  [35]. Following initial exposure, the virus establishes a 154 
lifelong latent infection that can periodically reactivate with shedding of infectious vi rus, although 155 
this rarely results in a clinically significant infection in healthy individuals. In contrast,  156 
reactivation is responsible for significant mortality and morbidity in immunocompromised 157 
patients  [35]. CMV replication involves the cleaving of concatameric genomic viral DNA and the 158 
packaging of each genome into preformed viral  capsids. This process is mediated by the CMV - 159 
terminase complex ( UL51, UL56, and UL89)  [36].  160 
Risk factors asso ciated with CMV reactivation include seropositivity of  the recipient while 161 
undergoing therapy immunosuppressive therapy with auto logous  or allo geneic  transplant or 162 
drugs like high dose steroids or alemtuzumab. Clinica l manifestations  include interstitial 163 
pneumonitis, encephalitis, retinitis, fevers, hepatitis, hemorrhagic cystitis and diarrhea  [37]. 164 
Current management focuses on reduction in immunosuppression and initiation of antiviral 165 
therapies including ganciclovir, cidofovir , foscarnet, and v alganciclovir  [37, 38] . Use of these 166 
agents, while necessary, carries significant side effect profiles including marrow suppression 167 
and nephrotoxicity . Furthermore, the development of antiviral resistance via mutations to CMV 168 
UL97 or UL54 genes limits the available agents effecti ve against CMV  [38].  Antiviral drug 169 
resistance shou ld be suspected in patients who  fail to improve ( i.e., >1 log 10 increase in CMV 170 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 9 of 57 
 DNA levels in blood or serum) after 2 weeks of appropriately dosed antiviral therapy  [38]. 171 
Although the incidence of drug r esistant CMV remains low (0 -8%)[39, 40] , it can still pose 172 
significant challenges to treatment when it occurs. Therefore, novel therapies to reduce the risk 173 
of CMV reactivation are needed in  order to avoid serious side effects of  antiviral therapies and 174 
to avoid drug resistance to these agents.  175 
A review o f published studies using alemtuzumab in the target patient population for this trial is 176 
summarized in Table 1. This shows that the CMV reactivation rate  in this patient population is 177 
~30%.  178 
Table 1: Reported r ates of CMV reactivation  with alemtuzumab  in target patient 179 
population  180 
Ref Population  CMV 
Reactivation 
(n) Total 
Patients 
(n) Reactivation 
Rate  CMV 
Prophy * Chemo 
Combination  Front 
Line 
Therapy  Relapsed 
Therapy  
[34] PTCL, T -
PLL, T -LGL, 
T-ALL, MF  9 24 38% Y Y Y Y 
[41] HTLV+ 
ATLL  29 29 100%  Y N Y Y 
[42] PTCL  5 20 25% N Y Y N 
[43] PTCL  5 41 12% N Y Y N 
[32] PTCL  7 20 35% N Y Y N 
[44] PTCL  12 38 32% N Y Y Y 
[33] PTCL  16 31 52% N Y Y N 
[45] T-PLL 13 21 62% N Y Y N 
[46] PTCL, T -
ALL 6 13 46% N Y Y Y 
[47] PTCL  8 15 53% N Y Y N 
[48] PTCL  8 24 33% N Y N Y 
[49] SS 3 5 60% N Y N Y 
[30] SS 3 14 21% N N Y Y 
[50] CTCL  10 39 26% N N Y Y 
[51] T-LGL 6 13 46% N N Y Y 
[20] CLL, PLL, 
CTCL, 
PTCL, T -
LGL, MCL, 
HCL 15 78 19% N N Y Y 
[52] SS 2 5 40% N N Y Y 
[21] T-PLL 3 76 4% N N Y Y 
[28] PTCL  6 14 43% N N N Y 
[53] CLL, PLL  5 34 15% N N N Y 
[54] MF, SS  0 10 0% N N N Y 
[55] PTCL, CTCL  1 10 10% N N N Y 
[56] MF, SS  1 8 13% N N N Y 
[57] MF, SS  4 22 18% N N N Y 
[58] MF, SS  0 18 0% N N N Y 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 10 of 57 
 Ref Population  CMV 
Reactivation 
(n) Total 
Patients 
(n) Reactivation 
Rate  CMV 
Prophy * Chemo 
Combination  Front 
Line 
Therapy  Relapsed 
Therapy  
[59] SS 3 6 50% N N N Y 
[60] PTCL 10 20 50% NR Y Y N 
[61] PTCL  5 16 31% NR Y N Y 
[62] PTCL  1 10 10% NR Y N Y 
[18] T-PLL 2 9 22% NR N Y N 
[22] T-PLL 1 39 3% NR N Y Y 
[19] T-PLL 1 15 7% NR N N Y 
[63] SS 6 13 46% NR N N Y 
[64] SS 1 1 100%  NR N N Y 
[65] SS 3 6 50% NR N NR NR 
[66] NHL, PTCL, 
AML, ALL, 
MDS, AA  66 180 37% Variable  Y Y Y 
                  
  TOTAL  276 937 29%         
                  
*CMV prophylaxis defined as  planned routine use of : ganciclovir (any dose), valganciclovir (any dose), foscarnet (any dose), 
acyclovir (>3200 mg by mouth per day or >25 mg/kg IV per day), valacyclovir (>3000 mg by mouth per day), or famciclovir 
(>1500 mg by mouth daily).  
 
Abbreviations: AA = aplastic anemia, ALL = T -cell acute lymphoblastic leukemia, AML = acute myeloid leukemia, ATLL = 
adult T -cell leukemia/lymphoma, CLL = chronic lymphocytic leukemia, CMV = cytomegalovirus, CTCL = cutaneous T -cell 
lymphoma, HCL = hairy ce ll leukemia, HTLV = human T -lymphotropic virus, MCL = mantle cell lymphoma, MDS = 
myelodysplastic syndrome, MF = mycosis fungoides, N = no, NHL = non -Hodgkin lymphoma, NR = not reported, PLL = 
prolymphocytic leukemia,  Prophy = prophylaxis,  PTCL = periphera l T cell lymphoma, SS = Sézary  syndrome,  T -LGL = T -cell 
large granular lymphocytic leukemia, Y = yes  
1.4 Letermovir  181 
Letermovir is  a highly potent anti -CMV agent recently FDA approved for anti -CMV prophylaxis 182 
post-transplant  based on the results of a recent randomized phase  3 trial [67]. Letermovir  183 
inhibits CMV replication by binding components of the terminase complex resulting in impaired  184 
cleavage and packaging of viral DNA into capsids  [68, 69]. 185 
In the trial leading to FDA approval , 565 CMV seropositive patients without detectable CMV 186 
DNA at baseline undergoing allogeneic hematopoietic stem cell transplantation were 187 
randomized to receive letermovir prophylaxis or placebo through week 14 after transplantation. 188 
Patients treated with let ermovir experienced a statistically significant decrease in clinically 189 
significant CMV infection compared to placebo (37.5% vs 60.6%, P<0.001). Additionally, the 190 
frequency and severity of adverse events were statistically similar between the two groups 191 
overall. Patients in the letermovir group may have experienced slightly higher rates of nausea 192 
and vomiting, peripheral edema, and atrial fibrillation. Importantly,  the use of letermovir 193 
prophylaxis  was associated with a trend toward lower all -cause mortality  compared to placebo  194 
in this trial  and this was confirmed in a  post hoc analysis of survival  [70].  195 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 11 of 57 
 Based on these data and the high rate of CMV reactivation following alemtuzumab  therapy, we 196 
propose the following phase 2 clinical trial of letermovir prophylaxis in patients with hematologic 197 
malignancies receiving alemtuzu mab.  198 
2 OBJECTIVES AND ENDPOINTS  199 
2.1 Objectives  200 
2.1.1  Primary Objective  201 
1. To estimate the rate of CMV reactivation in pat ients treated with letermovir at  3 months 202 
after completion of alemtuzumab therapy.  203 
2.1.2  Secondary Objectives  204 
1. To evaluate the tolerability of letermovir in  combination with alemtuzumab  205 
2. To evaluate the efficacy of letermovir for the prevention of clinically significant CMV 206 
disease  207 
3. To estimate the overall survival o f patients in the study population  208 
2.1.3  Exploratory Objectives  209 
1. To evaluate mechanisms of antivira l resistance in  letermovir prophylaxis failures.   210 
2.2 Endpoints  211 
2.2.1  Primary Endpoint  212 
1. CMV reactivation as defined in section 10.2. 213 
2.2.2  Secondary Endpoints  214 
1. Adverse events (AEs) using NCI Common Terminology Criteria for Adverse Events 215 
(CTCAE) version 5.  216 
2. Development of CMV disease per the Disease Definitions Working Group of th e 217 
Cytomegalovirus Drug Development Forum  [71] (Appendix 12.1) 218 
3. Overall  survival as defined in section 10.3 219 
2.2.3  Exploratory Endpoints  220 
1. Genotyping to evaluate mutations in CMV terminase complex genes (UL51, UL56, 221 
UL89 ) [72-79] 222 
3 PATIENTS AND MET HODS  223 
3.1 Inclusion Criteria  224 
1. Confirmed diagnosis of any lymphoid malignancy including, but not limited to, T-cell or 225 
B-cell prolymphocytic leukemia, chronic lymphocytic leukemia, peripheral T -cell 226 
lymphoma, cutaneous T -cell lymphoma, Sézary syndrome , or large granular lymphocytic 227 
leukemia . 228 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 12 of 57 
 2. Intent to treat with alemtuzumab. Monotherapy or combination with chemotherapy is 229 
allowed.  230 
3. Confirmed seropositivity for CMV IgG  (≥0.7 U/mL)  within 1 year of first letermovir dose.  231 
4. Confirmed lack of active CMV infection as evidenced by CMV DNA PCR ≤ 200 IU/mL 232 
and no clinical evidence of CMV disease  within  14 days of first letermovir dose.  233 
5. Age ≥18 years old  234 
6. Able to provide informed consent.  235 
7. Life expectancy >4 months  236 
8. Eastern Cooperative Oncology Group  (ECOG) performance sta tus ≤ 3 (Appendix 12.2) 237 
9. Highly unlikely to become pregnant or impregnate a partner by meeting at least one of 238 
the following:  239 
a. A female subject who is not of reproductiv e potential is eligible without requiring 240 
the use of contraception. A female subject who is not of reproductive poten tial is 241 
defined as one who:  242 
i. has reached natural menopause (defined as 6 months of spontaneous 243 
amenorrhea with serum follicle -stimulating ho rmone [FSH] levels in the 244 
postmenopausal range as determined by the local laboratory, or 12 245 
months of spontaneous amenorrhea)  246 
OR 247 
ii. is 6 weeks post -surgical bilateral oophorectomy with or without 248 
hysterectomy  249 
OR 250 
iii. has undergone bilateral tubal ligation. Spontan eous amenorrhea does not 251 
include cases for which there is an underlying disease that causes 252 
amenorrhea (e.g., anorexia nervosa).  253 
b. A male subject who is not of reproductive potential is eligible without requiring the 254 
use of contraception. A male subject who is not of reproductive potential is 255 
defined as one whom has undergone a successful defined as:  256 
i. microscopic documentation of azoospermia  257 
OR 258 
ii. a vasectomy more than 2 years ago with no resultant pregnancy despite 259 
sexual activity post -vasectomy  260 
c. A male or female subject who is of reproductive potential agrees to true 261 
abstinence or to u se (or have their partner use) an  acceptable method of birth 262 
control starting from the time of consent through 90 days after the last dose of 263 
study therapy. True abstinence is  defined as abstinence in line with the preferred 264 
and usual lifestyle of the subject. Periodic abstinence (e.g., abstinence only on 265 
certain calendar days, abstinence only during ovulation period, use of 266 
symptothermal method, use of post -ovulation methods) and withdrawal are not 267 
acceptable methods of contraception. Acceptabl e methods of birth control are:  268 
i. intrauterine device (IUD), diaphragm with spermicide, contraceptive 269 
sponge, condom, and vasectomy OR use of appropriate double barrier 270 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 13 of 57 
 contraception. Hormo nal contraceptives (e.g., birth control pills, 271 
transderm al patch, or injectables) are also acceptable . 272 
3.2 Exclusion Criteria  273 
1. History of confirmed CMV disease within 1 year of study entry.  274 
2. History of prior allogeneic hematopoietic stem cell transplant  within 6 months of trial 275 
enrollment . Subjects who have undergone allogeneic transplant more than 6 months 276 
prior to enrollment are eligible as long as the subject is off immunosuppression without 277 
active GVHD . 278 
3. End stage renal disease with c reatinine clearan ce < 10 mL/min as defined by  Cockcroft - 279 
Gault equation using serum creatinine within 7 days of enrollment  280 
a. Creatinine clearance (males) = (Weight  in kg)(140 −age )
(72)(creatinine  in mg/dL) 281 
b. Creatinine clearance (females) = (Weight  in kg)(140 −age )
(72)(creatinine  in mg/dL)∗0.85 282 
4. Severe hepatic impairment defined as : 283 
a.  Child -Pugh class C ( see appendix 12.2) within 7 days of enrollment  284 
b. Serum aspartate aminotransferase (AST) or alan ine aminotran sferase (ALT) > 5 285 
times  the upper limit of normal (ULN) or serum total bilirubin > 2.5 x ULN.  286 
Note:  Subjects who meet this exclusion criterion may, at the discretion of the 287 
investigator, have one repeat testing done. If the repeat value does not meet this 288 
criterion, they may continue in the screening process. Only the specific out of 289 
range value should be repeated (not the entire panel).  290 
5. Both moderate hepatic insufficiency AND moderate renal insufficiency:  291 
a. Moderate hepatic insufficiency is defined as Child Pugh Class B (see Appendix 292 
12.2) 293 
b. Moderate renal insufficiency is defined as a creatinine clearance less than 50 294 
mL/min, as calculated by the Cockcroft -Gault equation (as above)  295 
6. Cytopenias are NOT an exclusion criteria  in this trial as cytopenias are  comm on in this 296 
patient population and letermovir has no known adverse effects on blood counts. 297 
Patients will be treated per ins titutional standard of care with as needed transfusions and 298 
growth factor support.  299 
7. Received any of the following drugs within 7 days of enrollment  or plans to receive any 300 
of the following during the study:  301 
a. ganciclovir  302 
b. valganciclovir  303 
c. foscarnet  304 
d. acyclovir (at doses > 3200 mg PO per day or > 25 mg/kg IV per day)  305 
e. valacyclovir (at doses > 3000 mg PO per day)  306 
f. famciclovir (at doses > 1500 mg PO per day)  307 
g. Cyclosporin e A 308 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 14 of 57 
 h. Pimozide  309 
i. Ergot alkaloids (ergotamine and dihydroergotamine)  310 
j. Atorvastatin at doses greater than 20 mg daily (see Table 5) 311 
8. Received any of the following within 30 days prior to enrollment  312 
a. cidofovir  313 
b. CMV hyper -immune globulin  314 
c. Any investigational CMV antiviral agent/biologic therapy  315 
9. Infec tion or underlying disease necessitating ongoing use of pro hibited medications 316 
(Section 4.3).  317 
10. Suspected or known hypersensitivity to active or inactive ingredients o f letermovir 318 
formulations  319 
11. Positive at the time of screening for:  320 
a. HIV with CD4 count <350. If HIV positive, must remain on antiretroviral therapy 321 
that is not anticipated to interact with letermovir  throughout study.  322 
b. Hepatitis B surface antigen or core antib ody positivity associated with detectable 323 
viral load. For any patient with serologic evidence of prior infection but 324 
undetectable viral load, viral load and surface antigen will be monitored every 2 325 
weeks. Those with evidence of reactivation (detectable vi ral load) will be treated 326 
with ente cavir or lamivudine. Upon resolution of detectable viral load, the patient 327 
will be allowed to continue on trial assuming adequate liver function as defined 328 
above. Alternatively, patients may be put on prophylactic entecav ir or lamivudine 329 
to prevent hepatitis B reactivation at the investigators discretion.  330 
c. Hepatitis C if no prior or current curative antiviral therapy. For those currently on 331 
curative antiviral therapy, they will be allowed on trial if HCV quantitation is be low 332 
the limit of detection and adequate liver function as above.  333 
12. Pregnant or expecting to conceive, is breastfeeding, or plans to breastfeed from the time 334 
of consent through 90 days after the last dose of study therapy.  335 
13. Expecting to donate eggs or sperm starting from the time of consent through 90 days 336 
after the last dose of study therapy.  337 
14. Currently participating or has participated in a study with an unapproved investigational 338 
compound or device within 28 days, or 5X half -life of the investigationa l compound 339 
(excluding monoclonal antibodies), whichever is longer, of initial dosing on this study. 340 
Subjects previously treated with a monoclonal antibody will be eligible to participate after 341 
a 28-day washout period.  342 
15. Previous participation in a study usin g letermovir.  343 
16. Has a history or current evidence of any condition, therapy, lab abnormality, or other 344 
circumstance that might confound the results of the study, interfere with the subject's 345 
participation for the full duration of the study, or would be put at undue risk as judged by 346 
the investigator, such that it is not in the best interest of the subject to participate in this 347 
study  348 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 15 of 57 
 3.3 Screening  Procedures  349 
Patients may be screened for study entry when the determination has been made by the 350 
treating physician that they need therapy with alemt uzumab. Application to receive 351 
alemtuzumab for compassionate use would be started by the treating physician team, as per 352 
standard of care, while patient is being screened for trial. Application for compassionate u se of 353 
alemtuzumab can be accessed here:  https://www.campathproviderportal.com .  354 
4 TREATMENT PLAN  355 
4.1 Premedication Administration  356 
No premedication is necessary for letermovir .  357 
4.2 Agent Administration  358 
Letermovir will be administered at 480 mg by mouth daily starting up to two week s after the first 359 
administration of alemtuzumab. Treatment will continue for 3 month s after the last dose of 360 
alemtuzumab is given.  361 
If for any reason, t he subject is unable to take the oral formulation of letermovir for an extended 362 
period of time, the intravenous  (IV) formulation  of letermovir may be use . Simultaneous use of 363 
IV and oral study therapy is not allowed.  The IV formulation should be switched t o oral study 364 
therapy (i.e., at the next planned dose) as soon as such subjects are able to swallow and/or the 365 
condition necessitating the use of the IV formulation resolve . 366 
Study therapy with letermovir may begin as early as the first day of alemtuzumab in fusion to no 367 
later than 14 days after the first alemtuzumab infusion, once the subject is determined to be 368 
negative for active CMV infection as outlined in the inclusion criteria. Letermovir should continue 369 
through 90 days after the final planned alemtuzum ab infusion.  370 
Study therapy should be administered at the same time each day. Tablets are to be swallowed 371 
whole (i.e., no crushing or chewing the tablet is allowed). Study therapy may be administered 372 
with or without food.  373 
If a subject misses a dose, the mi ssed dose should be given as soon as possible during the 374 
same day. If more than 18 hours have gone by after the regular dosing time, then the missed 375 
dose should be skipped and the normal dosing schedule should be resumed. The next dose 376 
should not be double d in order to “make up” what has been missed.  377 
Study therapy can be administered with or without food. Subjects must avoid consumption of 378 
grapefruit, Seville oranges or their respective juices, and other quinine -containing drinks or food 379 
during the trial from 2 weeks prior to study drug administration until 72 hours after the final 380 
administration of study drug.  381 
4.3 Rationale for Dose Selection  382 
Please refer to the letermovir  package insert  for further details of preclinical data and study 383 
results in human s.  384 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 16 of 57 
 Letermovir  belongs to a new class of anti -CMV agents which have a different mechanism of 385 
action compared to currently available drugs for the treatment of CMV infection. By inhibiting the 386 
viral terminase complex, the drug plays a key role in cleavage a nd packaging of genomic virus 387 
DNA into provirions.  388 
Letermovir  is anticipated to be efficacious based on both the in vitro  potency of letermovir as 389 
well as its in vivo  efficacy  for CMV prophylaxis  in a Phase II I trial in allogeneic hematopoietic 390 
stem cell transplantation (HSCT)  recipients  [67]. In this trial, 565 CMV seropositive patients 391 
without detectable CMV DNA at baseline undergoing allogeneic HSCT were randomized to 392 
receive letermovir prophylaxis (480 mg daily or 240 mg daily or patients concomitantly recei ving 393 
CsA) or placebo through week 14 after transplantation. Patients treated with letermovir 394 
experienced a statistically significant decrease in clinically significant CMV infection compared 395 
to placebo (37.5% vs 60.6%, P<0.001). Additionally, the frequency  and severity of adverse 396 
events were statistically similar between the two groups overall. Patients in the letermovir group 397 
may have experienced slightly higher rates of nausea and vomiting, peripheral edema, and 398 
atrial fibrillation.  399 
Based on all available  safety data, letermovir  efficacy in the Phase II  and III  studies, and the 400 
exposure -response data, this study will use a dose of 480 mg daily . Patients who have had 401 
allogeneic transplant within 6 months prior to trial enrollment and patients receiving cyclosporin e 402 
A (CsA)  are excluded; phase I studies have demonstrated that co -admi nistration of letermovir 403 
with CsA  increases letermovir exposure ~3 fold.  Patients who have undergone allogeneic 404 
transplant more than 6 months prior to enrollment are eligible as long as the subject is off 405 
immunosuppression without active GVHD.  406 
4.4 Concomitant Medications and Supportive Care  407 
Allowed Medications/Therapies  408 
The follo wing medications/therapies  are allowed  in this study:  409 
• Standard antimicrobial prophylaxis (e.g., levofloxacin for bacteria, fluconazole/ 410 
voriconazole/posaconazole for fungi)  411 
• Acyclovir, valacyclovir, or famciclovir for prophylaxis of herpes simplex virus (H SV) or 412 
varicella zoster virus (VZV) infections at doses no greater than prohibited doses of these 413 
medications (see below)  414 
Prohibited Medications/Therapies   415 
The following medications/therapie s are prohibited  in this study:  416 
Antiviral drugs or therapies for prevention/treatment of CMV, including but not limited to:   417 
• ganciclovir  418 
• valganciclovir  419 
• foscarnet  420 
• cidofovir  421 
• acyclovir (at doses > 3200 mg PO per day or > 25 mg/kg IV per day)  422 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 17 of 57 
 • valacyclovir (at doses > 3000 mg PO per day)  423 
• famciclovir (at doses > 1500 mg PO per day)  424 
• CMV hyper -immune globulin  425 
• any investigational CMV antiviral agent/biologic therapy  426 
• CMV vaccine  427 
Investigational Agents   428 
Investigational agents are not permitted with the following exceptions: (1) Investigational 429 
chemotherapy regimens involving approved agents and (2) investigational antimicrobial 430 
regimens involving approved antibacterial/antifungal/antiviral agents.  431 
Other Agents:  432 
• Cyclosporin e A 433 
• Pimozide  434 
• Ergot alkaloids (ergotamine and dihydroergotamine)  435 
• Atorvastatin at doses greater th an 20 mg daily ( see Table 5) 436 
Medications/Therapies to be Administered with Caution   437 
Preclinical studies suggest MK -8228 acts as a weak to moderate inhibitor of cytochrome 438 
(CYP)3A4, CYP2C8, CYP2B6 and the transporters OAT P1B1 and OATP1B3. It is therefore 439 
possible that MK -8228 may increase the exposure of co -administered drugs whose primary 440 
route of clearance involves these enzymes or transporters.  Please see Table 5 (section 8.3) 441 
for a list of potentially clinically significant drug interactions.   442 
5 TOXICITIES, DOSE DEL AYS, AND DOSE MODIFICATIONS  443 
The NCI Common Terminology Criteria for Adverse Events (CTCAE) v5 will be used to grade 444 
adverse events.  445 
Subjects enrolled in this study will be evaluated clinically and with standard laboratory tests 446 
before and at regular inter vals during their participation in this study as specified in Study 447 
Calendar & Evaluations.  448 
Subjects will be evaluated for adverse events (all grades), serious adverse events, and adverse 449 
events requiring study drug interruption or discontinuation as speci fied in  Study Calendar & 450 
Evaluations (section 6).  451 
5.1 Dose Delays and Modifications  452 
Dose modific ations are not allowed on trial.  453 
5.2 Protocol Therapy Discontinuation  454 
Subjects may withdraw consent at any time for any reason or be dropped from the trial at the 455 
discretion of the investigator should any untoward effect occur. In addition, a subject may be 456 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 18 of 57 
 withdrawn by the investigator or the Sponsor if enro llment into the trial is inappropriate, the trial 457 
plan is violated, or for administrative and/or other safety reasons.  458 
A subject must  be discontinued from the trial for any of the following reasons:  459 
• CMV reactivation as defined in section 10.2 at any time during the study period, study 460 
therapy will be discontinued and the subject may be treated according to the local 461 
standard of care (outside the context of the study).  In this setting, any of the prohibited 462 
anti-CMV medications (outlined in section 4.4) may be used.  463 
• The subject becomes pregnant during the study  464 
• The subject’s invest igator feels it is in the best interest of the subject to discontinue.  465 
A subject may be discontinued from therapy for any of the following reasons:  466 
• Any AE/SAE assessed by the physician investigator as possibly or probably related to 467 
study therapy. Investig ator may continue the subject in the trial if it is deemed to be in the 468 
best interest of the subject to stay on study therapy.  469 
• Failure to comply with the dosing, evaluations, or other requirements of the trial.  470 
• The subject has a medical condition or person al circumstance which, in the opinion of the 471 
investigator and/or Sponsor, places the subject at unnecessary risk through continued 472 
participation in the trial or does not allow the subject to adhere to the requirements of the 473 
protocol.  474 
6 STUDY EVALUATIONS  475 
6.1 Calendar of Events  476 
Cycle  = 28 days  Screen ( -28 
days)  On 
Treatment1 At CMV 
reactivation2 AE follow 
up3 
REQUIRED  ASSESSMENTS  
Review of eligibility criteria,  informed 
consent  X    
Medical h istory  X    
ECOG PS4 X    
Physical exam, v ital signs5 X X X X 
AEs, concomitant medications  X X X X 
Drug diary   X X  
Assessment of contraception  method6 X    
CMV disease assessment7   X X 
LABORATORY ASSESSMENTS  
Complete blood cell count with differential 
(CBC)  X X X X 
Comprehensive metabolic profile (CMP)8 X X X X 
Prothrombin time (INR)  X    
Urine p regnancy test in WOCBP  X X X X 
HIV, hepatitis B, and hepatitis C screen9 X    
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 19 of 57 
 CMV IgG10 X    
CMV viral load11 (at least every other 
week , weekly preferred ) X X X X 
CORRELATIVE STUDIES (SPECIMEN COLLECTION)  
CMV Genotyping    X  
1. On study visits will occur every 28 days (+/ - 7 days) . Treatment with letermovir should be continued for 90 after the last dose of 
alemtuzumab.  
2. CMV reactivation defined as CMV DNA by real time polymerase chain reaction >500 IU/mL  
3. AE follow up to occur 30 days (+/ - 7 days) from last dose of letermovir therapy.  If patients have any ongoing toxicity related to 
letermovir, investigator should continue to monitor and provide appropriate supportive care. If patient ha s active CMV infection or 
reactivation, investigator should continue to monitor and provide appropriate treatment including antiviral therapy .  
4. See Appendix 12.2 
5. Vital signs include height, weight, blood pressure, heart rate, respiratory rate, temperature  
6. See section 3.1 for acceptable methods of co ntraception  
7. CMV disease assessment is a focused history and physical exam guided by known manifestations of CMV disease (see Appendix 
12.1). CMV disease assessment is to be performed if reactivation occurs as defined in Section 10.2. 
8. CMP should include at least the following: sodium, potassium, chloride,  creatinine, glucose, calcium, phosphorus, total bilirubin, 
AST, ALT, alkaline phosphatase, albumin.  
9. Screening to be completed with: HIV antibody, hepatitis B surface antibody, hepatitis B surface antigen, hepatitis B core ant ibody, 
hepatitis C antibody. I f hepatitis B surface antigen or core antibody is positive, hepatitis B viral load quantification with PCR should 
be ordered; if hepatitis C antibody is positive, viral load quantification by PCR should be ordered.  
10. CMV IgG seropositivity may be confirmed u p to 1 year prior to starting letermovir.  
11. CMV viral load testing by PCR will be completed at least every other week  while on therapy with letermovir.  Weekly monitoring is 
preferred but can be reduced to every 2 weeks at the investigator’s discretion. Window for screening is within 2 weeks of first dose 
of letermovir.  
 
6.2 Biospecimen Studies and Procedures  477 
The correlative studies will include g enotyping to evaluate mutations in CMV terminase complex 478 
genes (UL51, UL56, UL89)  through Viracor.  479 
6.3 Source and Timing of Biospecimen Collections  480 
Peripheral blood of approximately 10 ml in EDTA  (lavender top) tube will be inverted to mix anti - 481 
coagulant and then kept at room temperature until transport to the OSU Leukemia Tissue Bank 482 
(LTB) . Plasma and PBMCs will be separated and cryopreserved by standard methods. Samples 483 
will be labeled with the study time point, collection date and protocol number as we ll as study 484 
participant number. Frozen plasma samples would be batch analyzed after the completion of 485 
the study for CMV genotyping studies.  486 
6.4 Storage of Biospecimens  487 
Samples will be stored in OSU LTB.  488 
7 CRITERIA FOR DISEASE EVALUATION  489 
CMV reactivation is defined i n section 10.2. CMV disease will be defined as in Disease 490 
Definitions Working Group of the Cytomegalovirus Drug Development Forum  [71] (Appendix 491 
12.1). 492 
8 LETERMOVIR  INFORMATION   493 
8.1 Letermovir  Description and Mechanism of Action  494 
Letermovir  inhibits  the CMV  DNA  termi nase  complex  (pUL51,  pUL56,  and pUL89)  which  is 495 
required  for viral DNA processing and packaging. Biochemical characterization and electron 496 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 20 of 57 
 microscopy demonstrated that letermovir affects the production of proper unit length genomes 497 
and interferes with viri on maturation. Genotypic characterization of virus resistant to letermovir 498 
confirmed that letermovir targets the terminase complex.  499 
The median EC50 value of letermovir against a collection of clinical CMV isolates in a cell - 500 
culture model of infection was 2 .1 nM (range = 0.7 nM to 6.1 nM, n = 74). There was no 501 
significant difference in EC50 value by CMV gB genotype (gB1=29; gB2=27; gB3=11; and 502 
gB4=3).  No antagonism of the antiviral activity was seen when letermovir was combined with 503 
CMV DNA polymerase inhibitors (cidofovir, foscarnet, or ganciclovir).  504 
8.2 Clinical Pharmacology  505 
Letermovir has a molecular formula of C29H28F4N4O4 and a molecular weight of 572.55. The 506 
chemical name f or letermovir is (4S) -2-[8-Fluoro -2-[4-(3-methoxyphenyl)piperazin -1-yl]-3-[2- 507 
methoxy -5(trifluoromethyl)phe nyl]-3,4-dihydroquinazolin -4-yl] acetic acid. Letermovir is very 508 
slightly soluble in water.  509 
The chemical structure of letermovir is:  510 
 511 
 512 
8.3 Pharmacokinetics and Drug Metabolism  513 
The pharmacokinetic properties of letermovir are displayed in Table 2.  514 
Table 2: Absorption, Distribution, Metabolism, Elimination (ADME), and P harmacokinetic  515 
Properties of letermovir  516 
Pharmacokinetics in HSCT Recipients  
Treatment Regimen  Steady -state median (90% prediction interval)  
 AUC (ng•hr/mL) of letermovir  
480 mg oral once daily, no cyclosporine  34,400 (16,900, 73,700)  
480 mg IV once daily, no cyclosporine  100,000 (65,300, 148,000)  
240 mg oral once daily, with cyclosporine  60,800 (28,700, 122,000)  
240 mg IV once daily, with cyclosporine  70,300 (46,200, 106,000)  
Pharmacokinetics in Healthy Subjects  

Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 21 of 57 
 Treatment Regimen  Steady -state geometric mean AUC and Cmax of  
 letermovir  
480 mg oral once daily  Cmax: 13,000 ng/mL  
 AUC: 71,500 ng•hr/mL  
Dose proportionality  Greater than proportional following single and 
multiple oral or IV doses of letermovir  240 mg 
and 480 mg  
Accumulation ratio† Cmax: 1.03  
AUC: 1.22  
Time to steady -state  9-10 days  
Absorption  
Bioavailability  Healthy subjects administered letermovir  without 
cyclosporine: 94% at an oral dose range of 240 
mg to 480 mg  
HSCT recipients administered letermovir  without 
cyclosporine: 35% with 480 mg oral once  daily 
HSCT recipients administered letermovir  with 
cyclospo rine: 85% with 240 mg oral once  daily 
Median Tmax (hr)  45 min to 2.25 hr  
Effect of food (relative to fasting) ‡ AUC: 99.63% [84.27% - 117.80%]  
Cmax: 129.82% [104.35% -161.50%]  
Distribution  
Mean steady -state volume of distribution  45.5 L following IV administration in HSCT 
recipients  
% In vitro  bound to human plasma proteins  99% across the concentration range of 0.2 to 50 
mg/L  
In vitro  blood -to plasma ratio  0.56 across the concentration range of 0.1 to 10 
mg/L  
Metabolism  
In vitro  metabolism  UGT1A1/1A3 (minor)  
Drug -related component in plasma  97% unchanged parent  
No major metabolites detected in plasma  
Elimination  
Route of elimination  Hepatic uptake (OATP1B1/3)  
Mean terminal t 1/2 (hr) 12 hrs after dosing of letermovir  480 mg IV once 
daily 
% of dose excreted in feces§ 93% 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 22 of 57 
 % of dose excreted in urine§ <2% 
% of unchanged drug excreted in feces§ 70% 
* Values were obtained in studies of healthy subjects unless otherwise indicated.  
† Based on geometric mean data.  
‡ Values refer to geometric mean ratio [fed/fasted] percentage and 90% confidence interval back 
transformed from linear mixed -effects model performed on natural log -transformed values. The meal 
administered was a standard high fat and high calorie meal (33 grams protein, 65 grams 
carbohydrates, 58 grams fat; 920 total calories).  
 
§ Single oral administration of radiolabeled letermovir in mass balance study.  
 
 517 
Specific Populations  518 
Pediatric Population  519 
The pharmacokinetics of letermovir in patients less than 18 years of age have not been 520 
evaluated.  521 
Age, Gender, Race, and Weight  522 
Age (18 to 78 years), gender, race (White vs. non -White), and body weight (up to 100 kg) did 523 
not have a clinically significant effec t on the pharmacokinetics of letermovir.  524 
Renal Impairment  525 
Letermovir AUC was approximately 1.9 -and 1.4 -fold higher in subjects with moderate (eGFR 526 
greater than or equal to 30 to 59 mL/min/1.73m2) and severe (eGFR less than 30 527 
mL/min/1.73m2) renal impairmen t, respectively, compared to healthy subjects.  528 
Hydroxypropyl betadex present in the intravenous letermovir formulation is mainly eliminated by 529 
glomerular filtration. Decreased elimination of hydroxypropyl betadex has been reported in the 530 
literature in pati ents with severe renal impairment.  531 
Hepatic Impairment  532 
Letermovir AUC was approximately 1.6 -and 3.8 -fold higher in subjects with moderate (Child - 533 
Pugh Class B [CP -B], score of 7 -9) and severe (Child -Pugh Class C [CP -C], score of 10 -15) 534 
hepatic impairment, re spectively, compared to healthy subjects.  535 
Drug Interaction Studies   536 
Drug interaction studies were performed in healthy subjects with letermovir  and drugs likely to 537 
be co -administered or drugs commonly used as probes for pharmacok inetic interactions (see   538 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 23 of 57 
 Table  3 and   539 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 24 of 57 
 Table  4). 540 
In vitro  results indicate that letermovir is a substrate of drug metabolizing enzymes CYP3A, 541 
CYP2D6, UGT1A1, and UGT1A3, and transporters OATP1B1/3 and P -gp. Oxidative 542 
metabolism is considered to be a minor elimination pathway based on in vivo  human data. 543 
Inhibitors of OATP1B1/3 may result in increases in letermovir plasma concentrations. Changes 544 
in letermovir plasma concentrations due to inhibition of P -gp or UGTs are n ot anticipated to be 545 
clinically relevant.  546 
Based on in vitro  studies, the metabolism of letermovir is not mediated by CYP1A2, CYP2A6, 547 
CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2E1, CYP4A11, UGT1A4, UGT1A6, 548 
UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B4, UGT2B7,  UGT2B15, or UGT2B17. The 549 
transport of letermovir is not mediated by OATP2B1, OCT1, OAT1, BCRP, or MRP2 in vitro . 550 
Letermovir is a time -dependent inhibitor and inducer of CYP3A in vitro . Co-administration of 551 
letermovir  with midazolam resulted in increased e xposure of midazolam, indicating that the net 552 
effect of letermovir on CYP3A is moderate inhibition (see   553 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 25 of 57 
 Table  4). Based on these results, co -administration of letermovir  with CYP3A substrates may 554 
increase the plasma concentrations of the CYP3A substrates (see   555 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 26 of 57 
 Table  4). Letermovir is a reversible inhibitor of CYP2C8 in vitro . When co -administered with 556 
letermovir , plasma concentrations of CYP2C8 substrates are predicted  to be increased ( see   557 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 27 of 57 
 Table  4). Co-administration of letermovir  reduced the exposure of voriconazole, most likely due 558 
to the induction of voriconazole elimination pathways, CYP2C9 and CYP2C19. Co - 559 
administration of letermov ir with CYP2C9 and CYP2C19 substrates may decrease the plasma 560 
concentrations of the  CYP2C9 and CYP2C19 substrates ( see Table 5). Letermovir is an inducer 561 
of CYP2B6 in vitro ; the clinical relevance is unknown.  562 
Letermovir inhibited efflux transporters P -gp, breast cancer resistance protein (BCRP), bile salt 563 
export pump (BSEP), multidrug resistance -associated protein 2 (MRP2), OAT3, and hepatic 564 
uptake transporter OATP1B1/3 in vitro . Co-administration of letermovir  with substrates of 565 
OATP1B1/3 transporters (e.g. atorvastatin, a known substrate of CYP3A, OATP1B1/3, and 566 
potentially BCRP) may result in a clinically relevant increase in plasma concentr ations of 567 
OATP1B1/3 substrates ( see Table 5). There were no clinically relev ant changes in plasma 568 
concentrations of digoxin, a P -gp substrate, or acyclovir, an OAT3 substrate, following co - 569 
administration with letermovir  in clinical studies (see   570 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 28 of 57 
 Table  4). The effect of letermovir on BCRP, BSEP, and MRP2 substrates was not evaluated in 571 
clinical studies; the clinical relevance is unknown.  572 
Based on in vitro  results letermovir is not an inhibitor  of CYP1A2, CYP2A6, CYP2C9, CYP2C19, 573 
CYP2D6, CYP2E1, UGT1A4, UGT1A6, UGT1A9, or UGT2B7 and is not an inducer of CYP1A2. 574 
Letermovir is not an inhibitor of MRP2, OATP2B1, BSEP , OCT1, OCT2, or OAT1 in vitro . 575 
  576 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 29 of 57 
 Table 3: Drug Interaction s: Changes in Pharmacokinetics of Letermovir in the Presence 577 
of Co -administered Drug  578 
 
Co-   
administered 
Drug   
Regimen of 
Co-   
administered 
Drug   
Letermovir 
Regimen  Geometric Mean Ratio [90% CI] of 
Letermovir PK with/without  
Co-administered Drug 
(No Effect=1.00)  
AUC  Cmax  C24hr*  
Immunosuppressants  
 
cyclosporine  200 mg single 
dose PO  240 mg 
once daily 
PO 2.11 
(1.97, 2.26)  1.48 
(1.33, 1.65)  2.06 
(1.81, 2.35)  
mycophenolate 
mofetil  1 g single 
dose PO  480 mg 
once daily 
PO 1.18 
(1.04, 1.32)  1.11 
(0.93, 1.34)  1.39 
(1.12, 1.74)  
 
tacrolimus  5 mg single 
dose PO  80 mg 
twice daily 
PO 1.02 
(0.97, 1.07)  0.92 
(0.84, 1.00)  1.02 
(0.93, 1.12)  
Abbreviations: PO= oral  
* C12hr for tacrolimus  
 579 
  580 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 30 of 57 
 Table 4: Drug Interactions: Changes in Pharmacokinetics for Co -administered Drug in the 581 
Presence of Letermovir  582 
 
Co-   
administered 
Drug   
Regimen of 
Co-   
administered 
Drug   
Letermovir 
Regimen  Geometric Mean Ratio  
[90% CI] of Co -administered Drug PK 
with/without Letermovir  
(No Effect=1.00)  
AUC  Cmax  C24hr*  
CYP3A Substrates  
midazolam  1 mg single 
dose IV  240 mg once 
daily PO  1.47 
(1.37, 1.58)  1.05 
(0.94, 1.17)  2.74 
(2.16, 3.49)  
midazolam  2 mg single 
dose PO  240 mg once 
daily PO  2.25 
(2.04, 2.49)  1.72 
(1.54, 1.92)  Not available  
P-gp Substrates  
digoxin  0.5 mg single 
dose PO  240 mg twice 
daily PO  0.88 
(0.80, 0.96)  0.75 
(0.63, 0.89)  0.90 
(0.84, 0.96)  
Immunosuppressants  
cyclosporine  50 mg single 
dose PO  240 mg once 
daily PO  1.66 
(1.51, 1.82)  1.08 
(0.97, 1.19)  2.19 
(1.80, 2.66)  
mycophenolate 
mofetil  1 g single dose 
PO 480 mg once 
daily PO  1.08 
(0.97, 1.20)  0.96 
(0.82, 1.12)  1.04 
(0.86, 1.27)  
tacrolimus  5 mg single 
dose PO  480 mg once 
daily PO  2.42 
(2.04, 2.88)  1.57 
(1.32, 1.86)  2.53 
(2.12, 3.03)  
sirolimus  2 mg single 
dose PO  480 mg once 
daily PO  3.40 
(3.01, 3.85)  2.76 
(2.48, 3.06)  3.15 
(2.80, 3.55)  
Antifungals and Antivirals  
acyclovir  400 mg single 
dose PO  480 mg once 
daily PO  1.02 
(0.87, 1.2)  0.82 
(0.71, 0.93)  1.13 
(0.94, 1.36)  
posaconazole  300 mg single 
dose PO  480 mg once 
daily PO  0.98 
(0.82, 1.17)  1.11 
(0.95, 1.29)  1.10 
(0.94, 1.30)  
voriconazole  200 mg twice 
daily PO  480 mg once 
daily PO  0.56 
(0.51, 0.62)  0.61 
(0.53, 0.71)  0.49 
(0.42, 0.57)  
HMG -CoA Reductase Inhibitors  
atorvastatin  20 mg single 
dose PO  480 mg once 
daily PO  3.29 
(2.84, 3.82)  2.17 
(1.76, 2.67)  3.62 
(2.87, 4.55)  
Oral Contraceptives  
ethinyl estradiol 
(EE) 
/levonorgestrel 
(LNG)  0.03 mg EE 
single dose PO   
480 mg once 
daily PO  1.42 
(1.32, 1.52)  0.89 
(0.83, 0.96)  1.57 
(1.45, 1.70)  
0.15 mg LNG 
single dose PO  1.36 
(1.30, 1.43)  0.95 
(0.86, 1.04)  1.38 
(1.32, 1.46)  
Abbreviations: PO=oral  
* C12hr reported for voriconazole.  
 583 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 31 of 57 
 Table 5: Potentially Significant Drug Interactions: Alteration in Dose May Be 584 
Recommended Based on Results from Drug Interaction Studies or Predicted 585 
Interactions* (Information in the Table Applies to Co -administration of Letermovir  and the 586 
Concomitant Drug witho ut Cyclosporine, Unless Otherwise Indicated)  587 
Concomitant Drug 
Class and/or Clearance 
Pathway: Drug Name  Effect on 
Concentration† Clinical Comments  
Anti-arrhythmic agents  
amiodarone  ↑ amiodarone  Close clinical monitoring for adverse events 
related to amiodarone is recommended during co - 
administration. Frequently monitor amiodarone 
concentrations when amiodarone is co - 
administered with letermovir . 
Anticoagulants  
warfarin  ↓ warfarin  When letermovir  is co-administered with 
warfarin, frequently monitor International  
Normalized Ratio (INR)§. 
Anticonvulsants  
phenytoin  ↓ phenytoin  When letermovir  is co-administered with  
phenytoin, frequently monitor phenytoin 
concentrations§. 
Antidiabetic agents  
Examples:  
glyburide, repaglinide, 
rosiglitazone  ↑ glyburide  
↑ repaglinide  
↑ rosiglitazone  When letermovir  is co-administered with 
glyburide, repaglinide, or rosiglitazone, frequently 
monitor glucose concentrations§. 
When letermovir  is co-administered with 
cyclosporine, use of repaglinide is not 
recommended.  
Antifungals  
voriconazole‡ ↓ voriconazole  If concomitant administration of voriconazole is 
necessary, closely monitor for reduced 
effectiveness of voriconazole§. 
Antimycobacterial  
rifampin  ↓ letermovir  Co-administration of letermovir  and rifampin is 
not recommended.  
Antipsychotics  
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 32 of 57 
 pimozide  ↑ pimozide  Co-administration is contraindicated  due to risk of 
QT prolongation and torsades de pointes  
Ergot alkaloids  
ergotamine, 
dihydroergotamine  ↑ ergotamine, 
dihydroergotamine  Co-administration is contraindicated  due to risk of 
ergotism  
HMG -CoA Reductase Inhibitors  
atorvastatin‡ ↑ atorvastatin  When letermovir  is co-administered with 
atorvastatin, do not exceed an atorvastatin dosage 
of 20 mg daily§. Closely monitor patients for 
myopathy and rhabdomyolysis.  
When letermovir  is co-administered with 
cyclosporine, use of atorvastatin is not  
recommended.  
pitavastat in, 
simvastatin  ↑ HMG -CoA 
reductase inhibitors  Co-administration of letermovir  and pitavastatin or 
simvastatin is not recommended.  
When letermovir  is co-administered with 
cyclosporine, use of either pitavastatin or 
simvastatin is contraindicated due to significantly 
increased pitavastatin or simvastatin 
concentrations and risk of myopathy or 
rhabdomyolysis  
fluvastatin, lovastatin, 
pravastatin, ros uvastatin  ↑ HMG -CoA 
reductase inhibitors  When letermovir  is co-administered with these 
statins, a statin dosage reduction may be 
necessary§. Closely monitor patients for myopathy 
and rhabdomyolysis.  
When letermovir  is co-administered with 
cyclosporine, use of lovastatin is not 
recommended.  
When letermovir  is co -administered with 
cyclosporine, refer to the statin  prescribing 
information for specific statin  dosing  
recommendations.  
Immunosuppressants  
cyclosporine‡ ↑ cyclosporine  
↑ letermovir  Decrease the dosage of letermovir  to 240 mg 
once daily  
Frequently monitor cyclosporine whole blood 
concentrations during treatment and after 
discontinuation of letermovir  and adjust the dose of 
cyclosporine accord ingly§. 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 33 of 57 
 sirolimus‡ ↑ sirolimus  When letermovir  is co-administered with sirolimus, 
frequently monitor sirolimus whole blood 
concentrations during treatment and after 
discontinuation of letermovir  and adjust the dose of 
sirolimus accordingly§. 
When letermovir  is co-administered with 
cyclosporine and sirolimus, refer to the sirolimus 
presc ribing information for specific sirolimus dosing 
recommendations§. 
tacrolimus‡ ↑ tacrolimus  Frequently monitor tacrolimus whole blood 
concentrations during treatment and after 
discontinuation of letermovir  and adjust the dose of 
tacrolimus accordingly§. 
Proton pump inhibitors  
omeprazole  ↓omeprazole  Clinical monitoring and dose adjustment may be 
needed.  
pantoprazole  ↓ pantoprazole  Clinical monitoring and dose adjustment may be 
needed.  
CYP3A Substrates  
Examples: alfentanil, 
fentanyl, midazolam, and 
quinidine  ↑ CYP3A substrate  When letermovir  is co-administered with a CYP3A 
substrate, refer to the prescribing information for 
dosing of the CYP3A substrate with a moderate 
CYP3A inhibitor§. 
When letermovir  is co-administered with 
cyclosporine, the combined effect on CYP3A 
substrates may be simila r to a strong CYP3A 
inhibitor. Refer to the prescribing information for 
dosing of the CYP3A substrate with a strong 
CYP3A inhibitor§. 
CYP3A substrates pimozide and ergot 
alkaloids are contraindicated  
* This table is not all inclusive.  
† ↓ =decrease, ↑=in crease  
‡ These interactions have been studied [see Package Insert: Clinical Pharmacology (12.3)] . 
§ Refer to the respective prescribing information.  
 588 
8.4 Preparation , Storage, and Administration : Oral Formulation  589 
Letermovir tablets are supplied in two formulations:  590 
• Letermovir  240 mg tablet: yellow oval tablet with “591” on one side and Merck logo on the 591 
other side.  592 
• Letermovir  480 mg tablet: pink oval, bi -convex tablet with “595” on one side and Merck 593 
logo on the other side.  594 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 34 of 57 
 Letermovir  tablets contain ei ther 240 mg or 480 mg of letermovir and the following inactive 595 
ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, 596 
microcrystalline cellulose, povidone 25, and film -coated with a coating material containing the 597 
following inac tive ingredients: hypromellose 2910, iron oxide red (only for 480 mg tablets), iron 598 
oxide yellow, lactose monohydrate, titanium dioxide, and triacetin, Carnauba wax is added as a 599 
polishing agent.  600 
Tablets should be swallowed whole with or without food.  601 
Store letermovir  tablets in the original package until use.  602 
Store letermovir  tablets at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C 603 
(59°F to 86°F)  604 
8.5 Preparation , Storage,  and Administration : Intravenous formulation  605 
Letermovir  injection is supplied in 30 mL single -dose vials containing either 240 mg/12 mL per 606 
vial (20 mg/mL) or 480 mg/24 mL per vial (20 mg/mL). The preparation and administration 607 
instructions are the same for either dose.  608 
Letermovir  vials are for single use only. Discard a ny unused portion.  609 
Preparation and Administration Instructions  610 
• Letermovir  must be diluted prior to intravenous (IV) use.  611 
• Inspect vial contents for discoloration and particulate matter prior to dilution . Letermovir  612 
injection is a clear colorless solution. Do not use the vial if the solution is discolored or 613 
contains visible particles.  614 
• Do not shake letermovir  vial. 615 
• Add one single -dose vial of letermovir  injection into a 250 mL pre -filled IV bag containing 616 
either 0.9%  Sodium Chloride Injection, USP or 5% Dextrose Injection, USP and mix bag 617 
gently. Do not shake. Only 0.9% Sodium Chloride and 5% Dextrose are chemically and 618 
physically compatible with letermovir  injection.  619 
• Use compatible IV bags and infusion set materials . Letermovir  injection is compatible with 620 
the following IV bags and infusion set materials . Letermovir  injection is not recommended 621 
with any IV bags or infusion set materials not listed below (note that letermovir  injection is 622 
not recommended for use with p olyurethane -containing IV administration set tubing).  623 
IV Bags Materials:  624 
Polyvinyl chloride (PVC), ethylene vinyl acetate (EVA) and polyolefin (polypropylene and 625 
polyethylene)  626 
Infusion Sets Materials:  627 
PVC, polyethylene (PE), polybutadiene (PBD), silicone r ubber (SR), styrene –butadiene 628 
copolymer (SBC), styrene -butadiene -styrene copolymer (SBS), polystyrene (PS)  629 
Plasticizers:  630 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 35 of 57 
 Diethylhexyl phthalate (DEHP), tris (2 -ethylhexyl) trimellitate (TOTM), benzyl butyl 631 
phthalate (BBP)  632 
Catheters:  633 
Radiopaque polyurethane  634 
• Once diluted, the solution of letermovir  is clear, and ranges from colorless to yellow. 635 
Variations of color within this range do not affect the quality of the product. Parenteral 636 
drug products should be inspected visually for particulate matter and discol oration prior to 637 
administration, whenever solution and container permit. Discard if discoloration or visible 638 
particles are observed.  639 
• The diluted solution is stable for up to 24 hours at room temperature or up to 48 hours 640 
under refrigeration at 2°C to 8°C ( 36°F to 46°F) (this time includes storage of the diluted 641 
solution in the intravenous bag through the duration of infusion).  642 
• Administer the entire contents of the intravenous bag by intravenous infusion via a 643 
peripheral catheter or central venous line at a constant rate over 1 hour. Do not 644 
administer as an IV bolus injection.  645 
Compatible Drug Products:  646 
The physical compatibility of letermovir  injection with selected injectable drug products was 647 
evaluated in two commonly available diluents . Letermovir  should n ot be co -administered 648 
through the same intravenous line (or cannula) with other drug products and diluent 649 
combinations except those listed below. Refer to the respective prescribing information of the 650 
co-administered drug(s) to confirm compatibility of sim ultaneous co -administration.  651 
List of Compatible Drug Products when letermovir  and Drug Products are Prepared in 0.9% 652 
Sodium Chloride Injection, USP:  653 
Ampicillin sodium, ampicillin sodium/sulbactam sodium, anti -thymocyte globulin, 654 
caspofungin, daptomycin, fe ntanyl citrate, fluconazole, furosemide, human insulin, 655 
magnesium sulfate, methotrexate, micafungin.  656 
List of Compatible Drug Products when letermovir  and Drug Products are Prepared in 5% 657 
Dextrose Injection, USP:  658 
Amphotericin B (lipid complex)*, anidulafung in, cefazolin sodium, ceftaroline, ceftriaxone 659 
sodium, doripenem, famotidine, folic acid, ganciclovir sodium, hydrocortisone sodium 660 
succinate, morphine sulfate, norepinephrine bitartrate, pantoprazole sodium, potassium 661 
chloride, potassium phosphate, tacrol imus, telavancin, tigecycline.  662 
*Amphotericin B (lipid complex) is compatible with letermovir . However, Amphotericin B 663 
(liposomal) is incompatible (see below)  664 
Incompatible Drug Products  665 
Letermovir  injection is physically incompatible with amiodarone hydrochloride, amphotericin B 666 
(liposomal), aztreonam, cefepime hydrochloride, ciprofloxacin, cyclosporine, diltiazem 667 
hydrochloride, filgrastim, gentamicin sulfate, levofloxacin, linezolid, lorazepam, mi dazolam HCl, 668 
mycophenolate mofetil hydrochloride, ondansetron, palonosetron.  669 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 36 of 57 
 Storage  670 
Store letermovir  injection vials at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 671 
30°C (59°F to 86°F).  672 
Store in the original carton to protect from exposure to light.  673 
8.6 Non Clinical Toxicology  674 
8.6.1  Carcinogenesis, Mutagenesis, Impairment of Fertility  675 
Carcinogenesis and Mutagenesis  676 
Letermovir was not genotoxic in in vitro  or in vivo  assays, including microbial mutagenesis 677 
assays, chromosomal aberration in Chi nese hamster ovary cells, and in an in vivo  mouse 678 
micronucleus study.  679 
Carcinogenicity studies with letermovir have not been conducted.  680 
Impairment of Fertility  681 
In a fertility and early embryonic development study in rats, no effects of letermovir on female  682 
fertility were observed at letermovir exposures (AUC) approximately 5 times higher than human 683 
exposure at the RHD.  684 
In male rat fertility studies, decreased fertility associated with irreversible testicular toxicity was 685 
observed at  686 
≥180 mg/kg/day (greater than or equal to 3 times the human exposure at the RHD). No fertility 687 
or testicular effects were observed at dose levels resulting in letermovir exposures (AUC) similar 688 
to human exposure at the RHD [see Nonclinical Toxicology (13.2)].  689 
8.6.2  Animal Toxicology and  Pharmacology  690 
Testicular toxicity in rats observed at ≥180 mg/kg/day (greater than or equal to 3 times the 691 
human exposure at the RHD) was characterized by decreased testis weight, bilateral 692 
seminiferous tubular degeneration, decreased sperm count and motil ity, and resultant 693 
decreased male fertility. Male reproductive system toxicities were not observed in either a 694 
monkey testicular toxicity study up to 240 mg/kg/day (approximately 2 times higher than human 695 
exposure at the RHD), or a general toxicology study  in mice up to 250 mg/kg/day 696 
(approximately 3 times higher than human exposure at the RHD).  697 
8.7 Clinical Studies  698 
To evaluate letermovir  prophylaxis as a preventive strategy for CMV infection or disease in 699 
transplant recipients at high risk for CMV reactivation , the efficacy of letermovir  was assessed in 700 
a multicenter, double -blind, placebo -controlled Phase 3 Trial (P001, [STUDY_ID_REMOVED]) in adult 701 
CMV -seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT). 702 
Subjects were randomized (2 :1) to receive either letermovir  at a dose of 480 mg once daily 703 
adjusted to 240 mg when co -administered with cyclosporine, or placebo. Randomization was 704 
stratified by investigational site and risk level for CMV reactivation at the time of study entry. 705 
Study drug was initiated after HSCT (at any time from Day 0 to Day 28 post -transplant) and 706 
continued through Week 14 post -transplant. Study drug was administered either orally or 707 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 37 of 57 
 intravenously; the dose of letermovir  was the same regardless of the route of adm inistration. 708 
Subjects received CMV DNA monitoring weekly until post -transplant Week 14 and then bi - 709 
weekly until post - transplant Week 24, with initiation of standard -of-care CMV pre -emptive 710 
therapy if CMV viremia was considered clinically significant. Subj ects had continued follow -up 711 
through Week 48 post -transplant.  712 
Among the 565 treated subjects, 70 subjects were found to have CMV viremia prior to study 713 
drug initiation and were therefore excluded from the efficacy analyses. The efficacy population 714 
consiste d of 325 subjects who received letermovir  (including 91 subjects who received at least 715 
one IV dose) and 170 who received placebo (including 41 subjects who received at least one IV 716 
dose). The IV formulation of letermovir  was used at investigators’ discreti on in subjects who 717 
were unable to take oral therapy (e.g., unable to tolerate oral intake). The median time to 718 
starting study drug was 8 days after transplantation. Thirty -four percent (34%) of subjects were 719 
engrafted at baseline. The median age was 55 yea rs (range: 18 to 76 years); 57% were male; 720 
84% were White; 9% were Asian; 2% were Black or African American; and 7% were Hispanic or 721 
Latino.  722 
At baseline, 30% of all subjects had one or more of the following factors associated with 723 
increased risk for CMV re activation (high risk stratum): Human Leukocyte Antigen (HLA) -related 724 
donor with at least one mismatch at one of the following three HLA -gene loci: HLA -A, -B or –DR; 725 
haploidentical donor; unrelated donor with at least one mismatch at one of the following f our 726 
HLA-gene loci: HLA -A, -B, -C and -DRB1; use of umbilical cord blood as stem cell source; use 727 
of ex vivo T -cell-depleted grafts; Grade 2 or greater Graft- Versus -Host Disease (GVHD) 728 
requiring systemic corticosteroids. The remaining 70% of subjects did n ot meet any of these 729 
high risk stratum criteria and were therefore included in the low risk stratum. Additionally, 48% 730 
of subjects received a myeloablative regimen, 51% were receiving cyclosporine, and 43% were 731 
receiving tacrolimus. The most common primary  reasons for transplant were acute myeloid 732 
leukemia (38%), myelodysplastic syndrome (16%), and lymphoma (12%).  733 
Clinically Significant CMV Infection  734 
The primary efficacy endpoint of Trial P001 was the incidence of clinically significant CMV 735 
infection throug h Week 24 post -transplant (prophylaxis failure). Clinically significant CMV 736 
infection was defined as the occurrence of either CMV end -organ disease, or initiation of anti - 737 
CMV pre -emptive therapy (PET) based on documented CMV viremia (using the Roche 738 
COBAS®  AmpliPrep/COBAS TaqMan® assay, LLoQ is 137 IU/mL, which is approximately 150 739 
copies/mL) and the clinical condition of the subject. The protocol-  740 
specified guidance for CMV DNA thresholds for the initiation of PET during the treatment period 741 
was ≥ 150 copi es/mL or > 300 copies/mL for subjects in the high and low risk strata, 742 
respectively. From Week 14 through Week 24, the threshold was >300 copies/mL for both high 743 
and low risk strata subjects. The Non - Completer=Failure (NC=F) approach was used, where 744 
subje cts who discontinued from the trial prior to Week 24 post -transplant or had a missing 745 
outcome at Week 24 post -transplant were counted as failures.  746 
Efficacy results from Trial P001 are shown in .  747 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 38 of 57 
 Table 6.  748 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 39 of 57 
 Table 6: Trial P001 Efficacy Results in HSCT Recipients (NC=F Approach, FAS 749 
Population) Through Week 24  750 
 
Parameter  Letermovir 
(N=325)  Placebo 
(N=170)  
 
Proportion of subjects who failed prophylaxis 
Reasons for failures*   
 
38%  
 
61% 
Clinically significant CMV infection by Week 24† 18% 42% 
Initiation of PET based on documented CMV 
viremia  16% 40% 
CMV end-organ disease  2% 2% 
Discontinued from study before Week 24‡ 17% 16% 
Missing outcome in Week 24 visit window  
Stratum -adjusted treatment  difference 
(Letermovir -Placebo)§ 
Difference (95%  CI) 3% 
 
 
-23.5 ( -32.5, -14.6)¶ 3% 
* The categories of failure are mutually exclusive and based on the hierarchy of categories in the order listed.  
† Through Week 14, 8% of subjects in the letermovir  group and 39% of subjects in the placebo group experienced clinically 
significant CMV infection.  
‡ Reasons for discontinuation included adverse event, death, lost to follow -up, physician decision, and withdrawal by subject.  
§ 95% CI and p -value for the treatment differences in percent response were calculated using stratum -adjusted Mantel -Haenszel 
method with the difference weighted by the harmonic mean of sample size per arm for each stratum (high or low risk).  
¶ p-value <0.0001.  
Note: FAS=Full analysis set; FAS includes randomized subjects who received at least one dose of study medication, and 
excludes subje cts with detectable CMV DNA at baseline. Approach to handling missing values: Non -Completer=Failure 
(NC=F) approach. With NC=F approach, failure was defined as all subjects who developed clinically significant CMV infection 
or prematurely discontinued from  the study or had a missing outcome through Week 24 post -transplant visit window.  
 751 
Efficacy results were consistent across high and low risk strata for CMV reactivation. The time 752 
to clinically significant CMV infection is shown in   753 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 40 of 57 
 Figure  1. 754 
  755 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 41 of 57 
 Figure 1: P001: Kaplan -Meier Plot of Time to Onset of Clini cally Significant CMV Infection 756 
Through Week 24 Post -Transplant in HSCT Recipients (FAS Population)  757 
 758 
Post-hoc analysis demonstrated that among letermovir -treated subjects, inclusion in the high 759 
risk stratum for CMV reactivation at baseline, occurrence of GVHD, and steroid use at any time 760 
after randomization may be associated with the development of clinicall y significant CMV 761 
infection between Week 14 and Week 24 post -transplant.  762 
Mortality  763 
The Kaplan -Meier event rate for all -cause mortality in the letermovir vs. placebo groups was 764 
12% vs. 17% at Week 24 post -transplant, and 24% vs. 28% at Week 48 post-transplant.  765 
8.8 Adverse Events  766 
Adult CMV -seropositive Recipients [R+] of an Allogeneic HSCT  767 
The safety of letermovir was evaluated in one Phase 3 randomized, double -blind, placebo - 768 
controlled trial (P001) in which 565 subjects were randomized and treated w ith letermovir 769 
(N=373) or placebo (N=192) through Week 14 post -transplant. Adverse events were those 770 
reported while subjects were on study medication or within two weeks of study medication 771 
completion/discontinuation. The mean time for reporting adverse ev ents and laboratory 772 
abnormalities was approximately 22% longer in the letermovir arm compared to the placebo 773 
arm. 774 

Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 42 of 57 
 Cardiac Adverse Events:  775 
The cardiac adverse event rate (regardless of investigator -assessed causality) was higher in 776 
subjects receiving leterm ovir (13%) compared to subjects receiving placebo (6%). The most 777 
common cardiac adverse events were tachycardia (reported in 4% of letermovir subjects and in 778 
2% of placebo subjects) and atrial fibrillation (reported in 3% of letermovir subjects and in 1% o f 779 
placebo subjects). Among those subjects who experienced one or more cardiac adverse events, 780 
85% of letermovir and 92% of placebo subjects had events reported as mild or moderate in 781 
severity.  782 
Common Adverse Events  783 
The rate of adverse events occurring in a t least 10% of subjects in the letermovir group and at a 784 
frequency at least 2% greater than placebo are outlined in Table 7.  785 
Table 7: Trial P001 All Grade Adverse Events Reported in ≥ 10% of Letermovir -Treated 786 
HSCT Recipients at a Frequency at least 2% Greater than Placebo  787 
Adverse Events  Letermovir 
(N=373)  Placebo 
(N=192)  
nausea  27% 23% 
diarrhea  26% 24% 
vomiting  19% 14% 
peripheral edema  14% 9% 
cough  14% 10% 
headache  14% 9% 
fatigue  13% 11% 
abdominal pain  12% 9% 
 788 
Overall, similar proportions of subjects in each group discontinued study medication due to an 789 
adverse event (13% of letermovir subjects vs. 12% of placebo subjects). The most frequently 790 
reported adverse event that led to study drug discontinuation was nausea, occurring in 2% of 791 
letermovir subjects and 1% of placebo subjects. Hypersensitivity reaction, with associated 792 
moderate dysp nea, occurred in one subject following the first infusion of IV letermovir after 793 
switching from oral letermovir, leading to treatment discontinuation.  794 
Laboratory Abnormalities  795 
Selected laboratory abnormalities reported during treatment or within 2 weeks of  stopping 796 
treatment are presented in Table 8. 797 
Table 8: Trial P001 Selected Laboratory Abnormalities  798 
 
Letermovir  
N=373  Placebo 
N=192  
Absolute neutrophil count (cells/μL)    
< 500  19% 19% 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 43 of 57 
 500 – < 750  4% 7% 
750 – < 1000  8% 9% 
Hemoglobin (g/dL)    
< 6.5  2% 1% 
6.5 – < 8.0  14% 15% 
8.0 – < 9.5  41% 43% 
Platelets (cells/μL)    
< 25000  27% 21% 
25000 – < 50000  17% 18% 
50000 – < 100000  20% 30% 
Serum creatinine (mg/dL)    
> 2.5  2% 3% 
> 1.5 – 2.5 17% 20% 
 799 
The median time to engraftment (defined as absolute neutrophil count ≥ 500/mm3 on 3 800 
consecutive days after transplantation) was 19 days in the letermovir  group and 18 days in the 801 
placebo group.  802 
9 REGULATORY AND REPORTING REQUIREMENTS  803 
9.1 Adverse Events (AEs)  804 
Definition: any unfavorable medical occurrence in a human subject including any abnormal sign, 805 
symptom, or disease.  806 
For the purposes if this study, “Adverse Event” or “AE” shall mean any untoward medical 807 
occurrence i in a Study subject who is administ ered the Study Drug (letermovir) regardless 808 
of whether or not a causal relationship with th e Study Drug exists . By way of example and 809 
without limitation, a n AE can be any unfavorable and unintended sign (for example, an 810 
abnormal laboratory finding), sympto m, or disease temporally associated with the use of 811 
the Study Drug . 812 
Grading: the descriptions and grading scales found in the revised NCI Common Terminology 813 
Criteria for Adverse Events (CTCAE) version 5.0 will be utilized for all toxicity reporting. A copy  814 
of the CTCAE version 5.0 can be downloaded from the CTEP website.  815 
Attribution (relatedness), Expectedness, and Seriousness: the definitions for the terms listed 816 
that should be used are those provided by the Department of Health and Human Services’ 817 
Office for Human Research Protections (OHRP). A copy of this guidance can be found on 818 
OHRP’s website:  819 
http://www.hhs.gov/ohrp/policy/advevntguid.html  820 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 44 of 57 
 Unanticipated Problems Definition:  821 
• unexpected (in terms of nature, severity, or frequency) given (a) the research  procedures 822 
that are described in the protocol -related documents, such as the IRB - approved 823 
research protocol and informed consent document; and (b) the characteristics of the 824 
subject population being studied;  825 
• related or possibly related to participation i n the research (“possibly related” means there 826 
is a reasonable possibility that the incident, experience, or outcome may have been 827 
caused by the procedures involved  in the research);  828 
• Suggests that the research places subjects or others at a greater risk of  harm (including 829 
physical, psychological, economic, or social harm) than was previously known or 830 
recognized.  831 
9.2 Serious Adverse Events (SAEs)  832 
“Serious Adverse Event ” or “ SAE” shall mean any untoward medical occurrence in a Study 833 
subject who is administered th e Study Drug (letermovir) which meets one or more of the 834 
seriousness criteria outlined below.  835 
An adverse event should be classified as a serious adverse event if the following  seriousness  836 
criteria are met:  837 
• It results in death (i.e., the adverse event actua lly causes or leads to death)  838 
• It is life threatening (i.e., the adverse event, in the view of the investigator, places the 839 
subject at immediate risk of death. It does not include an adverse event that, had it 840 
occurred in a more severe form, might have caus ed death.).  841 
• It requires or prolongs inpatient hospitalization.  842 
• It results in persistent or significant disability/incapacity (i.e., the adverse event results in 843 
substantial disruption of the subject’s ability to conduct normal life functions).  844 
• It results i n a congenital anomaly/birth defect in a neonate/infant born to a mother 845 
exposed to the IMP.  846 
• It is considered a significant medical event by the investigator based on medical 847 
judgment (e.g., may jeopardize the subject or may require medical/surgical interv ention to 848 
prevent one of the outcomes listed above).  849 
“Suspected Unexpected Serious Adverse Reaction ” or “ SUSAR ” shall mean any Serious 850 
Adverse Event, the nature, severity or frequency of which is not consistent with information in 851 
the most current Summary of Product Characteristics (SPC) or Package Insert.  852 
9.3 Noncompliance  853 
Definition: failure to follow any applicable regulation or institutional policies that govern human 854 
subjects research or failure to follow the determinations of the IRB. Noncompliance may oc cur 855 
due to lack of knowledge or due to deliberate choice to ignore regulations, institutional policies, 856 
or determinations of the IRB.  857 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 45 of 57 
 9.4 Serious Noncompliance  858 
Definition: noncompliance that materially increases risks, that results in substantial harm to 859 
subje cts or others, or that materially compromises the rights or welfare of participants.  860 
9.5 Reporting to the OSU IRB  861 
The OSU PI is required to promptly notify the IRB of the following events:  862 
• Any unanticipated problems involving risks to participants or others wh ich occur at OSU, 863 
or that impacts participants or the conduct of the study.  864 
• Noncompliance with federal regulations or the requirements or determinations of the IRB.  865 
• Receipt of new information that may impact the willingness of participants to participate 866 
or continue participation in the research study.  867 
These events must be reported to the IRB within the time frames outlined in the IRB policy.  868 
9.6 Reporting to the sponsor  869 
Principal investigator shall forward to Merck’s Global Pharmacovigilance (“Mer ck GPV”) group, 870 
any SAE or SUSAR, including, but not limited to, all initial and follow up information involving 871 
any study subject in the study. Notification shall be in the form of a completed CIOMS 872 
I/MedWatch (or other mutually agreed upon format) within  two (2) business days of but not 873 
longer than three (3) calendar days of receipt of this information. This information shall be 874 
transmitted to Merck GPV using the contact information provided below or such other modified 875 
contact information as provided by Merck in writing. All information shall be transmitted in the 876 
English language and contain the reporter’s name and the study subject identifier code. SUSAR 877 
information will be reported unblinded if the study drug has been blinded in the study. 878 
Randomizatio n codes for all other SAEs will be provided to Merck GPV at end of study if the 879 
Study Drug has been blinded in the study.  880 
SAE reports and any other relevant safety information are to be forwarded to Merck GPV 881 
facsimile number: 215 -661-6229.  882 
9.7 Reporting to th e FDA  883 
The conduct of the study will comply with all FDA safety reporting requirements. PLEASE 884 
NOTE THAT REPORTING REQUIREMENTS FOR THE FDA DIFFER FROM REPORTING 885 
REQUIREMENTS FOR THE IRB.  It is the responsibility of the investigator to report any 886 
unanticipa ted problem to the FDA as follows:  887 
• Report any unexpected fatal or life -threatening adverse experiences associated with use 888 
of the drug (i.e., there is a reasonable possibility that the experience may have been 889 
caused by the drug) by telephone or fax no lat er than 7 calendar days after initial receipt 890 
of the information. A life -threatening adverse experience is defined as any adverse drug 891 
experience that places the subject (in the view of the investigator) at immediate risk of 892 
death from the reaction as it o ccurred, i.e., it does not include a reaction that, had it 893 
occurred in a more severe form, might have caused death.  894 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 46 of 57 
 • Report any serious, unexpected adverse experiences, as well as results from animal 895 
studies that suggest significant clinical risk within 15 calendar days after initial receipt of 896 
this information. A serious adverse drug experience is defined as any adverse drug 897 
experience occurring at any dose that results in any of the following outcomes:  898 
o Death  899 
o A life -threatening adverse drug experience  900 
o Inpat ient hospitalization or prolongation of existing hospitalization  901 
o A persistent or significant disability/incapacity (i.e., a substantial disruption of a 902 
person’s ability to conduct normal life functions)  903 
o A congenital anomaly/birth defect  904 
o Any other experienc e which, based upon appropriate medical judgment, may 905 
jeopardize the subject and may require medical or surgical intervention to 906 
prevent one of the outcomes listed above  907 
An unexpected adverse drug experience is defined as any adverse drug experience, the 908 
specificity or severity of which is not consistent with the current investigator brochure (or risk 909 
information, if an IB is not required or available).  910 
All MedWatch forms will be sent by the investigator or investigator’s team to the FDA (refer to 911 
the FDA w ebsite to obtain the current address and fax number for the Center for Drug 912 
Evaluation and Research Division of Oncology Drug Products).  913 
9.8 Timeframe for Reporting Required Events  914 
Reportable adverse events will be tracked for 30 days following the last day of  study treatment.  915 
Deaths  
Any reportable death while on study or 
within 30 days of study  Immediately, within 24 hours, to PI and the 
IRB 
Any reportable death while off study  Immediately, within 24 hours, to PI and the 
IRB 
Adverse Events/Unanticipated Problems  
Any reportable adverse events as described 
in Sections 9.1 and 9.2 (other than death) 
and 9.9  Immediately, within 24 hours to PI and 
within required time frame to the IRB (per 
local policy) and within 7 or 15 calendar 
days to  the FDA  
All adverse events regardless of grade and 
attribution should be submitted cumulatively  Include in DSM report  
Noncompliance and Serious Noncompliance  
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 47 of 57 
 All noncompliance and serious 
noncompliance as described in Sections 9.3 
and 9.4  Immediately, within 24 hours, to PI and 
within required time frame to the IRB (per 
local policy)  
 916 
9.9 Overdose  917 
In this trial, an overdose is any dose higher than two times the dose specified in  section 4.  918 
If an adverse event(s) is associated with (“results from”) the overdose of Sponsor's product, the 919 
adverse event(s) is reported as a serious adverse event, even if no other seriousness criteria 920 
are met. If a dose of Sponsor's product meeting the protocol de finition of overdose is taken 921 
without any associated clinical symptoms or abnormal laboratory results, the overdose is 922 
reported as a non -serious Event of Clinical Interest (ECI), using the terminology “accidental or 923 
intentional overdose without adverse eff ect.” All reports of overdose with and without an adverse 924 
event must be reported within 24 hours to the Sponsor either by electronic media or paper.  925 
There is no specific antidote for overdose with letermovir . In case of overdose, it is 926 
recommended that the patient be monitored for adverse reactions and appropriate symptomatic 927 
treatment be instituted.  928 
 929 
It is unknown whether dialysis will result in meaningful removal of letermovir  from systemic 930 
circulation.  931 
9.10 Pregnancies  932 
Pregnancies and susp ected pregnancies (including a positive pregnancy test regardless of age 933 
or disease state) of a woman occurring while on study  or within 28 days of her last dose of study 934 
drug are considered immediately reportable events. Protocol therapy  is to be disconti nued 935 
immediately. The pregnancy, suspected pregnancy, or positive pre gnancy test must be reported 936 
within 24 hours . 937 
All subjects who become pregnant must be followed to the completion/termination of the 938 
pregnancy. Pregnancy outcomes of spontaneous abortion,  missed abortion, benign hydatidiform 939 
mole, blighted ovum, fetal death, intrauterine death, miscarriage and stillbirth must be reported 940 
as serious events (Important Medical Events). CRFs will be used to report pregnancies and 941 
pregnancy outcomes . 942 
9.11 Data and s afety monitoring  943 
The data and safety monitoring plan will involve the continuous evaluation of safety, data quality 944 
and data timeliness. Investigators will conduct continuous review of data and patient safety at 945 
the regular protocol review meeting at least  monthly. The PI of the trial will review toxicities and 946 
responses of the trial where applicable and determine if the risk/benefit ratio of the trial changes. 947 
Frequency and severity of adverse events will be reviewed by the PI and compared to what is 948 
known  about the agent/device from other sources; including published literature, scientific 949 
meetings and discussions with sponsors, to determine if the trial should be terminated before 950 
completion. Serious adverse events and responses will also be reviewed by t he OSUCCC Data 951 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 48 of 57 
 and Safety Monitoring Committee (DSMC). The PI will also submit a progress report that will be 952 
reviewed by the committee per the DSMC plan. All reportable Serious Adverse Events (SAE) 953 
will be reported to the IRB of record as per the policies  of the IRB.  954 
9.11.1  Data Submission  955 
The study will be managed per OSU Clinical Trial Office.  Data will be directly entered into the 956 
OSU OnCore database . 957 
9.11.2  Auditing  958 
As the study sponsor, The Ohio State University Comprehensive Cancer Center (OSUCCC) will 959 
audit the trial per OSU policies. Audits will be performed by the OSUCCC Clinical Research 960 
Audit Team.  961 
9.12 Ethical Considerations  962 
The study will be conducted in accordance with ethical principles founded in the Declaration of 963 
Helsinki. Investigators and study staff will  undergo training on Good Clinical Practice (GCP) 964 
through the Collaborative Institutional Training Initiative (CITI). GCP training sets the standard 965 
for the design, conduct, recording, and reporting of studies involving human subjects, ensuring 966 
that study subjects rights, safety, and well -being are protected. The IRB will review all 967 
appropriate study documentation in order to safeguard the rights, safety and wellbeing of the 968 
patients. The study will only be conducted at sites where IRB approval has been obt ained. The 969 
protocol, informed consent form, written information given to the patients (including pill diaries), 970 
safety updates, annual progress reports, and any revisions to these documents will be provided 971 
to the IRB by the investigator, as allowable by l ocal regulations. The principal investigator will 972 
ensure that the study will be conducted according to the protocol and all applicable regulations. 973 
The protection of each subject’s rights and welfare will be maintained.  974 
9.13 Retention of records  975 
FDA regulations  (21 CFR § 312.62[c]) and the ICH Guideline for GCP (see Section 4.9 of the 976 
guideline) require that records and documents pertaining to the conduct of clinical trials and the 977 
distribution of investigational drug, patient records, consent forms, laboratory test results, and 978 
medication inventory records, must be retained for 2 years after the last marketing application 979 
approval in an ICH region or after at least 2 years have elapsed since formal discontinuation of 980 
clinical development of the investigational p roduct. All state and local laws for retention of 981 
records also apply.  982 
For studies conducted outside the United States under a U.S. IND, the Principal Investigator 983 
must comply with the record retention requirements set forth in the FDA IND regulations and t he 984 
relevant national and local health authorities, whichever is longer.  985 
10 STATISTICAL METHODS  986 
10.1 Study Design  and Sample Size Justification  987 
The primary objective of this single center, single arm phase II study is to determine the efficacy 988 
of letermovir prophyl axis in PLL, CLL, PTCL or CTCL patients treated with alemtuzumab. The 989 
efficacy will be measured through the CMV reactivation rate during letermovir prophylaxis (3 990 
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 49 of 57 
 months after completion of alemtuzumab therapy). All eligible patients who receive any 991 
leterm ovir will be included in the safety analysis, and all patients who receive ≥90% of planned 992 
letermovir doses are evaluable for the efficacy analysis.  993 
Fleming’s two -stage design [80] will be followed to conduct the study. Previous trials reported  994 
CMV reactivation rate of 30% in a similar patient population, and our own institutional data 995 
revealed a similar pattern.  Based on these data, we determined that a CMV reactivation rate of 996 
30% or higher is not acceptable, which leads to our null hypothesi s of a 70% safety rate. In a 997 
pivotal phase 3 trial, letermovir prophylaxis resulted in a clinically significant 23.1% absolute 998 
reduction (61.6% relative risk reduction) in CMV infection rate compared with placebo in 999 
recipients of allogeneic hematopoietic s tem cell transplantation without evidence of hematologic 1000  
toxicity  [67]. Therefore, we hypothesized that letermovir prophylaxis will reduce the CMV by 1001  
20% in our patient population to a 10% reactivation rate, which translat es to an alternative 1002  
hypothesis of 90% safety rate.  1003  
With a one -sided type I error rate of 5% and 85% power, Fleming’s two -stage design allows a 1004  
first-stage analysis after the first 14 patients are enrolled and evaluated. If 4 or more patients 1005  
have CMV rea ctivation durin g letermovir prophylaxis period , the regimen will be considered 1006  
inefficacious, and the study will be terminated early due to futility. On the other hand, if none of 1007  
the 14 patients experiences CMV reactivation, letermovir will be declared ef fective in preventing 1008  
CMV  reactivation , and the study will be ended early with rejection of the null hypothesis as the 1009  
final conclusion. If CMV infection is observed in between 1 to 3 patients among the first 14, then 1010  
the study will continue to accrue to a  total of 28 patients. By the end of the study, if at least 24 1011  
out of the 28 patients are CMV free, we will conclude the regimen effective to warrant further 1012  
investigation.     1013  
To account for the possibility that some patients might not be evaluable, we wi ll allow a 5% 1014  
over-accrual for a total target enrollment of 30 patients.  With a n anticipated accrual rate of 1.5  1015  
patients a month, the study is expected to complete enr olling for the first stage in 10 months. 1016  
With another 7  months for the primary endpoint  evaluation, the fir st stage will finish in about 17  1017  
months. If the second stage were to continue, the wh ole study can last as long as 27  months.     1018  
10.2 Analysis of Primary Objective  1019  
1. For efficacy analysis, the CMV reactivation rate will be defined as the proportion of 1020  
patients who experience CMV reactivation (CMV DNA by real time polymerase chain 1021  
reaction >500 IU/mL) during prophylaxis period among all patients who receive ≥90% of 1022  
planned letermovir doses.  The rate will be provided with 95% binomial confidence 1023  
interval.  1024  
10.3 Analysis of Secondary Objectives  1025  
1. All eligible patients who receive any letermovir prophylaxis will be included in the 1026  
tolerability  analysis. Adverse event data will be described and graded per the NCI 1027  
CTCAE v5.0 guidelines. The maximum grade for each type of toxicity will be recorded 1028  
for each patient, and frequency tables will be reviewed to determine toxicity patterns, 1029  
especially for grade 3 or above adverse events. To assess tolerability, we also capture 1030  
the proportion of patients who require dose reduction as well as those who go off 1031  
treatment due to adverse events.  1032  
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 50 of 57 
 2. Clinically significant CMV reactivation be determined per the Disease Definitions 1033  
Working Group of the C ytomegalovirus Drug Development Forum  [71] (Appendix 12.1). 1034  
3. OS of patients treated with alemtuzumab after letermovir prophylaxis will be calculated  1035  
from trial enrollment t o the occurrence of (death due to any cause), censoring event -free 1036  
patients at time of last follow -up. OS will be estimated with the method of Kaplan -Meier 1037  
(KM), where KM curves will be drawn to aid with visualization and estimates provided 1038  
with 95% confidence intervals.    1039  
10.4 Analysis of Exploratory Objectives  1040  
CMV DNA Sequence Analysis to be performed only in subjects with CMV reactivation . 1041  
Resistance to letermovir  will be monitored by retrospective genotypic analysis of the CMV 1042  
terminase gene UL56 in CMV DNA extracts from selected plasma samples collected at the time 1043  
of diagnosed CMV reactivation. Samples will be analyzed by standard population sequencing 1044  
technology through an established contract laboratory with validated protocols in place. If no 1045  
mutations are noted in UL56, then genotype testing will reflex to UL51 and UL89 (less frequent 1046  
resistance mutations have been reported in these genes).  1047  
11 REFERENCE S 1048  
 1049  
1. Foss, F.M., et al., Peripheral T -cell lymphoma.  Blood, 2011. 117(25): p. 6756 -6767.  1050  
2. Vose, J., et al., International peripheral T -cell and natural killer/T -cell lymphoma study: 1051  
pathology findings and clinical outcomes.  J Clin Onco l, 2008. 26(25): p. 4124 -30. 1052  
3. Morgensztern, D., et al., Lack of survival improvement in patients with peripheral T -cell 1053  
lymphoma: a Surveillance, Epidemiology, and End Results analysis.  Leuk Lymphoma, 1054  
2011. 52(2): p. 194 -204. 1055  
4. Weisenburger, D.D., et al ., Peripheral T -cell lymphoma, not otherwise specified: a report 1056  
of 340 cases from the International Peripheral T -cell Lymphoma Project.  Blood, 2011. 1057  
117(12): p. 3402 -8. 1058  
5. Abouyabis, A.N., et al., Incidence and outcomes of the peripheral T -cell lymphoma 1059  
subtypes in the United States.  Leuk Lymphoma, 2008. 49(11): p. 2099 -107. 1060  
6. Morton, L.M., et al., Lymphoma incidence patterns by WHO subtype in the United 1061  
States, 1992 -2001.  Blood, 2006. 107(1): p. 265 -76. 1062  
7. Hristov, A.C., T. Tejasvi, and R.A. Wilcox, Myco sis fungoides and Sezary syndrome: 1063  
2019 update on diagnosis, risk -stratification, and management.  Am J Hematol, 2019. 1064  
94(9): p. 1027 -1041.  1065  
8. Agar, N.S., et al., Survival outcomes and prognostic factors in mycosis fungoides/Sezary 1066  
syndrome: validation of t he revised International Society for Cutaneous 1067  
Lymphomas/European Organisation for Research and Treatment of Cancer staging 1068  
proposal.  J Clin Oncol, 2010. 28(31): p. 4730 -9. 1069  
9. Duvic, M., et al., Bexarotene is effective and safe for treatment of refractory advanced - 1070  
stage cutaneous T -cell lymphoma: multinational phase II -III trial results.  J Clin Oncol, 1071  
2001. 19(9): p. 2456 -71. 1072  
10. Olsen, E.A., et al., Phase IIb multicenter trial of vorinostat in patients with persistent, 1073  
progressive, or treatment refractory cutaneous T -cell lymphoma.  J Clin Oncol, 2007. 1074  
25(21): p. 3109 -15. 1075  
11. Mann, B.S., et al., Vorinostat for treatment of cutaneous manifestations of advanced 1076  
primary cutaneous T -cell lymphoma.  Clin Cancer Res, 2007. 13(8): p. 2318 -22. 1077  
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 51 of 57 
 12. Whittaker, S.J., et  al., Final results from a multicenter, international, pivotal study of 1078  
romidepsin in refractory cutaneous T -cell lymphoma.  J Clin Oncol, 2010. 28(29): p. 1079  
4485 -91. 1080  
13. Piekarz, R.L., et al., Phase II Multi -Institutional Trial of the Histone Deacetylase Inh ibitor 1081  
Romidepsin As Monotherapy for Patients With Cutaneous T -Cell Lymphoma.  Journal of 1082  
Clinical Oncology, 2009. 27(32): p. 5410 -5417.  1083  
14. Prince, H.M., et al., Brentuximab vedotin or physician's choice in CD30 -positive 1084  
cutaneous T -cell lymphoma (ALCANZA): an international, open -label, randomised, 1085  
phase 3, multicentre trial.  Lancet, 2017. 390(10094): p. 555 -566. 1086  
15. Kim, Y.H., et al., Mogamulizumab versus vorinostat in previously treated cutaneous T - 1087  
cell lymphoma (MAVORIC): an international, open -label, randomised, controlled phase 3 1088  
trial. Lancet Oncol, 2018. 19(9): p. 1192 -1204.  1089  
16. Matutes, E., et al., Clinical and laboratory features of 78 cases of T -prolymphocytic 1090  
leukemia.  Blood, 1991. 78(12): p. 3269 -74. 1091  
17. Sud, A. and C . Dearden, T-cell Prolymphocytic Leukemia.  Hematol Oncol Clin North Am, 1092  
2017. 31(2): p. 273 -283. 1093  
18. Dearden, C.E., et al., Alemtuzumab therapy in T -cell prolymphocytic leukemia: 1094  
comparing efficacy in a series treated intravenously and a study piloting the  1095  
subcutaneous route.  Blood, 2011. 118(22): p. 5799 -802. 1096  
19. Pawson, R., et al., Treatment of T -cell prolymphocytic leukemia with human CD52 1097  
antibody.  J Clin Oncol, 1997. 15(7): p. 2667 -72. 1098  
20. Ferrajoli, A., et al., Phase II study of alemtuzumab in chronic  lymphoproliferative 1099  
disorders.  Cancer, 2003. 98(4): p. 773 -8. 1100  
21. Keating, M.J., et al., Campath -1H treatment of T -cell prolymphocytic leukemia in patients 1101  
for whom at least one prior chemotherapy regimen has failed.  J Clin Oncol, 2002. 20(1): 1102  
p. 205 -13. 1103  
22. Dearden, C.E., et al., High remission rate in T -cell prolymphocytic leukemia with 1104  
CAMPATH -1H. Blood, 2001. 98(6): p. 1721 -6. 1105  
23. Krishnan, B., et al., Stem cell transplantation after alemtuzumab in T -cell prolymphocytic 1106  
leukaemia results in longer surv ival than after alemtuzumab alone: a multicentre 1107  
retrospective study.  Br J Haematol, 2010. 149(6): p. 907 -10. 1108  
24. Wiktor -Jedrzejczak, W., et al., Hematopoietic stem cell transplantation in T - 1109  
prolymphocytic leukemia: a retrospective study from the European Group for Blood and 1110  
Marrow Transplantation and the Royal Marsden Consortium.  Leukemia, 2012. 26(5): p. 1111  
972-6. 1112  
25. Guillaume, T., et al., Allogeneic hematopoietic stem cell transplantation for T - 1113  
prolymphocytic leukemia: a report from the French society for stem cell transplantation 1114  
(SFGM -TC). Eur J Haematol, 2015. 94(3): p. 265 -9. 1115  
26. Kalaycio, M.E., et al., Allogeneic hematopoietic cell transplant for prolymphocytic 1116  
leukemia.  Biol Blood Marrow Transplant, 2010. 16(4): p. 543 -7. 1117  
27. Poggio, T., J. Duyster, a nd A. Illert, Current Immunotherapeutic Approaches in T Cell 1118  
Non-Hodgkin Lymphomas.  Cancers, 2018. 10(9): p. 339.  1119  
28. Enblad, G., et al., A pilot study of alemtuzumab (anti -CD52 monoclonal antibody) 1120  
therapy for patients with relapsed or chemotherapy -refrac tory peripheral T -cell 1121  
lymphomas.  Blood, 2004. 103(8): p. 2920 -4. 1122  
29. Stewart, J.R., et al., Alemtuzumab is an effective third -line treatment versus single -agent 1123  
gemcitabine or pralatrexate for refractory Sezary syndrome: a systematic review.  Eur J 1124  
Dermato l, 2018. 28(6): p. 764 -774. 1125  
30. Bernengo, M.G., et al., Low-dose intermittent alemtuzumab in the treatment of Sezary 1126  
syndrome: clinical and immunologic findings in 14 patients.  Haematologica, 2007. 92(6): 1127  
p. 784 -94. 1128  
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 52 of 57 
 31. Watanabe, R., et al., Alemtuzumab th erapy for leukemic cutaneous T -cell lymphoma: 1129  
diffuse erythema as a positive predictor of complete remission.  JAMA Dermatol, 2014. 1130  
150(7): p. 776 -9. 1131  
32. Kluin -Nelemans, H.C., et al., Intensified alemtuzumab -CHOP therapy for peripheral T - 1132  
cell lymphoma.  Ann Oncol, 2011. 22(7): p. 1595 -600. 1133  
33. Roswarski, J., et al., Phase 1/2 study of alemtuzumab with dose -adjusted EPOCH in 1134  
untreated aggressive T and NK cell lymphomas.  Leuk Lymphoma, 2019. 60(8): p. 2062 - 1135  
2066.  1136  
34. Ravandi, F., et al., Phase II study of alemtu zumab in combination with pentostatin in 1137  
patients with T -cell neoplasms.  J Clin Oncol, 2009. 27(32): p. 5425 -30. 1138  
35. Cannon, M.J., D.S. Schmid, and T.B. Hyde, Review of cytomegalovirus seroprevalence 1139  
and demographic characteristics associated with infectio n. Rev Med Virol, 2010. 20(4): 1140  
p. 202 -13. 1141  
36. Borst, E.M., et al., The human cytomegalovirus UL51 protein is essential for viral 1142  
genome cleavage -packaging and interacts with the terminase subunits pUL56 and 1143  
pUL89.  J Virol, 2013. 87(3): p. 1720 -32. 1144  
37. Boec kh, M., et al., Cytomegalovirus in hematopoietic stem cell transplant recipients: 1145  
Current status, known challenges, and future strategies.  Biol Blood Marrow Transplant, 1146  
2003. 9(9): p. 543 -58. 1147  
38. El Chaer, F., D.P. Shah, and R.F. Chemaly, How I treat resistant cytomegalovirus 1148  
infection in hematopoietic cell transplantation recipients.  Blood, 2016. 128(23): p. 2624 - 1149  
2636.  1150  
39. Allice, T., et al., Valganciclovir as pre -emptive therapy for cytomegalovirus infection post - 1151  
allogenic stem cell transplantation: implications for the emergence of drug -resistant 1152  
cytomegalovirus.  J Antimicrob Chemother, 2009. 63(3): p. 600 -8. 1153  
40. Hantz, S., et al., Drug -resistant cytomegalovirus in transplant recipients: a French cohort 1154  
study.  J Antimicrob Chemother, 2010. 65(12): p.  2628 -40. 1155  
41. Sharma, K., et al., Phase II Study of Alemtuzumab (CAMPATH -1) in Patients with HTLV - 1156  
1-Associated Adult T -cell Leukemia/lymphoma.  Clin Cancer Res, 2017. 23(1): p. 35 -42. 1157  
42. Kim, J.G., et al., Alemtuzumab plus CHOP as front -line chemotherapy for patients with 1158  
peripheral T -cell lymphomas: a phase II study.  Cancer Chemother Pharmacol, 2007. 1159  
60(1): p. 129 -34. 1160  
43. Binder, C., et al., CHO(E)P -14 followed by alemtuzumab consolidation in untreated 1161  
peripheral T cell lymphomas: final analy sis of a prospective phase II trial.  Ann Hematol, 1162  
2013. 92(11): p. 1521 -8. 1163  
44. Weidmann, E., et al., A phase II study of alemtuzumab, fludarabine, cyclophosphamide, 1164  
and doxorubicin (Campath -FCD) in peripheral T -cell lymphomas.  Leuk Lymphoma, 1165  
2010. 51(3): p . 447 -55. 1166  
45. Hopfinger, G., et al., Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and 1167  
cyclophosphamide induction followed by alemtuzumab consolidation is effective in T -cell 1168  
prolymphocytic leukemia.  Cancer, 2013. 119(12): p. 2258 -67. 1169  
46. Kuan, J.W., et al., The Outcome of HyperCVAD Combined with Alemtuzumab for the 1170  
Treatment of Aggressive T -Cell and NK -Cell Neoplasms.  Indian J Hematol Blood 1171  
Transfus, 2011. 27(3): p. 136 -45. 1172  
47. Intragumtornchai, T., et al., Alemtuzumab in Combination with CHO P and ESHAP as 1173  
First-Line Treatment in Peripheral T -Cell Lymphoma.  Blood, 2006. 108(11): p. 4740 - 1174  
4740.  1175  
48. Kim, S.J., et al., Dose modification of alemtuzumab in combination with dexamethasone, 1176  
cytarabine, and cisplatin in patients with relapsed or refract ory peripheral T -cell 1177  
lymphoma: analysis of efficacy and toxicity.  Invest New Drugs, 2012. 30(1): p. 368 -75. 1178  
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 53 of 57 
 49. Rupoli, S., et al., Alemtuzumab in Combination with Interferon -α or Gemcitabine in 1179  
Aggressive and Advanced Cutaneous T -Cell Lymphomas: Report o f Preliminary Results.  1180  
Blood, 2008. 112(11): p. 5000 -5000.  1181  
50. de Masson, A., et al., Long -term efficacy and safety of alemtuzumab in advanced 1182  
primary cutaneous T -cell lymphomas.  Br J Dermatol, 2014. 170(3): p. 720 -4. 1183  
51. Dumitriu, B., et al., Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim 1184  
results from a single -arm, open -label, phase 2 study.  Lancet Haematol, 2016. 3(1): p. 1185  
e22-9. 1186  
52. Alinari, L., et al., Subcutaneous alemtuzumab for Sezary Syndrome in the very elderly.  1187  
Leuk Res, 2008. 32(8): p. 1299 -303. 1188  
53. Nguyen, D.D., et al., Cytomegalovirus viremia during Campath -1H therapy for relapsed 1189  
and refractory chronic lymphocytic leukemia and prolymphocytic leukemia.  Clin 1190  
Lymphoma, 2002. 3(2): p. 105 -10. 1191  
54. Querfeld, C., et al., Alemtuzuma b for relapsed and refractory erythrodermic cutaneous 1192  
T-cell lymphoma: a single institution experience from the Robert H. Lurie 1193  
Comprehensive Cancer Center.  Leuk Lymphoma, 2009. 50(12): p. 1969 -76. 1194  
55. Zinzani, P.L., et al., Preliminary observations of a p hase II study of reduced -dose 1195  
alemtuzumab treatment in patients with pretreated T -cell lymphoma.  Haematologica, 1196  
2005. 90(5): p. 702 -3. 1197  
56. Kennedy, G.A., et al., Treatment of patients with advanced mycosis fungoides and 1198  
Sezary syndrome with alemtuzumab.  Eur J Haematol, 2003. 71(4): p. 250 -6. 1199  
57. Lundin, J., et al., Phase 2 study of alemtuzumab (anti -CD52 monoclonal antibody) in 1200  
patients with advanced mycosis fungoides/Sezary syndrome.  Blood, 2003. 101(11): p. 1201  
4267 -72. 1202  
58. Clark, R.A., et al., Skin effector memory T cells do not recirculate and provide immune 1203  
protection in alemtuzumab -treated CTCL patients.  Sci Transl Med, 2012. 4(117): p. 1204  
117ra7.  1205  
59. Novelli, S., et al., Alemtuzumab treatment for Sezary syndrome: A single -center 1206  
experience.  J Dermatolog Trea t, 2016. 27(2): p. 179 -81. 1207  
60. Buckstein, R., et al., Alemtuzumab and CHOP Chemotherapy for the Treatment of 1208  
Aggressive Histology Peripheral T Cell Lymphomas: A Multi -Center Phase I Study.  Clin 1209  
Lymphoma Myeloma Leuk, 2016. 16(1): p. 18 -28 e4.  1210  
61. Kim, S.J. , et al., Alemtuzumab and DHAP (A -DHAP) is effective for relapsed peripheral 1211  
T-cell lymphoma, unspecified: interim results of a phase II prospective study.  Ann Oncol, 1212  
2009. 20(2): p. 390 -2. 1213  
62. Wulf, G.G., et al., Reduced intensity conditioning and allogeneic stem cell 1214  
transplantation after salvage therapy integrating alemtuzumab for patients with relapsed 1215  
peripheral T -cell non -Hodgkin's lymphoma.  Bone Marrow Transplant, 2005. 36(3): p. 1216  
271-3. 1217  
63. Beltran -Garate, B., et al., Alemtuzumab in Patients w ith Advanced Mycosis Fungoides 1218  
and Sezary Syndrome.  Blood, 2007. 110(11): p. 3425 -3425.  1219  
64. Oliveira, A., et al., Sezary syndrome presenting with leonine facies and treated with low - 1220  
dose subcutaneous alemtuzumab.  Dermatol Online J, 2011. 17(11): p. 6.  1221  
65. Fernandes, I.C., et al., Can the level of CD52 expression on Sezary cells be used to 1222  
predict the response of Sezary syndrome to alemtuzumab?  J Am Acad Dermatol, 2012. 1223  
67(5): p. 1083 -5. 1224  
66. Kim, S.J., et al., Non-bacterial infections in Asian patients treat ed with alemtuzumab: a 1225  
retrospective study of the Asian Lymphoma Study Group.  Leuk Lymphoma, 2012. 53(8): 1226  
p. 1515 -24. 1227  
67. Marty, F.M., et al., Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic -Cell 1228  
Transplantation.  N Engl J Med, 2017. 377(25): p.  2433 -2444.  1229  
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 54 of 57 
 68. Goldner, T., et al., The novel anticytomegalovirus compound AIC246 (Letermovir) 1230  
inhibits human cytomegalovirus replication through a specific antiviral mechanism that 1231  
involves the viral terminase.  J Virol, 2011. 85(20): p. 10884 -93. 1232  
69. Lischka, P., et al., In vitro and in vivo activities of the novel anticytomegalovirus 1233  
compound AIC246.  Antimicrob Agents Chemother, 2010. 54(3): p. 1290 -7. 1234  
70. Ljungman, P., et al., A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus 1235  
(CMV) in CMV -Seropositive Recipients of Allogeneic Hematopoietic -Cell 1236  
Transplantation.  Clin Infect Dis, 2019.  1237  
71. Ljungman, P., et al., Definitions of Cytomegalovirus Infection and Disease in Transplant 1238  
Patients for Use in Clinical Trials: Table 1.  Clinical Infectious Diseases, 2017. 64(1): p. 1239  
87-91. 1240  
72. Chou, S., A third component of the human cytomegalovirus terminase complex is 1241  
involved in letermovir resistance.  Antiviral Res, 2017. 148: p. 1 -4. 1242  
73. Lischka, P., D. Michel, and H. Zimmerma nn, Characterization of Cytomegalovirus 1243  
Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228).  J 1244  
Infect Dis, 2016. 213(1): p. 23 -30. 1245  
74. Chou, S., L.E. Satterwhite, and R.J. Ercolani, New Locus of Drug Resistance in the 1246  
Human C ytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and 1247  
Ganciclovir.  Antimicrob Agents Chemother, 2018. 62(9). 1248  
75. Chou, S., Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That 1249  
Confer Letermovir Resistance.  Antimicrob Age nts Chemother, 2015. 59(10): p. 6588 -93. 1250  
76. Goldner, T., et al., Geno - and phenotypic characterization of human cytomegalovirus 1251  
mutants selected in vitro after letermovir (AIC246) exposure.  Antimicrob Agents 1252  
Chemother, 2014. 58(1): p. 610 -3. 1253  
77. Chou, S.,  Comparison of Cytomegalovirus Terminase Gene Mutations Selected after 1254  
Exposure to Three Distinct Inhibitor Compounds.  Antimicrob Agents Chemother, 2017. 1255  
61(11). 1256  
78. Lischka, P., et al., Impact of glycoprotein B genotype and naturally occurring ORF UL56 1257  
polymorphisms upon susceptibility of clinical human cytomegalovirus isolates to 1258  
letermovir.  Antiviral Res, 2016. 132: p. 204 -9. 1259  
79. Goldner, T., H. Zimmermann, and P. Lischka, Phenotypic characterization of two 1260  
naturally occurring human Cytomegalovirus seque nce polymorphisms located in a 1261  
distinct region of ORF UL56 known to be involved in in vitro resistance to letermovir.  1262  
Antiviral Res, 2015. 116: p. 48 -50. 1263  
80. Fleming, T.R., One-sample multiple testing procedure for phase II clinical trials.  1264  
Biometrics, 198 2. 38(1): p. 143 -51. 1265  
 1266  
12 APPENDICES  1267  
12.1 CMV Disease Definitions Working Group of the Cytomegalovirus Drug 1268  
Development Forum  1269  
CMV Disease  Diagnostic criteria  Notes  
Pneumonia  Clinical symptoms and/or signs of 
pneumonia such as new infiltrates on 
imaging, hypoxia, tachypnea,  and/or 
dyspnea  
AND  • PCR may be too sensitive, so 
detection of CMV by PCR alone is 
insufficient for the diagnosi s of 
CMV pneumonia.  
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 55 of 57 
 CMV documented in BAL or lung 
tissue by virus isolation, rapid 
culture, histopathology, IHC, or DNA 
hybridization techniques  • Detection of fungal co -pathogens 
like Aspergillus spp. + "halo" sign 
(radiology) indicates fungal, rather 
than CMV pneumonia.  
• Superinfection or coinfection with 
other pathogens may occur and 
should be noted when present.  
GI Upper and/o r lower gastrointestinal 
(GI) symptoms  
AND  
macroscopic mucosal lesions  
AND  
CMV documented in tissue by 
histopathology, virus isolation, rapid 
culture, IHC, or DNA hybridization 
techniques.  • PCR may be too sensitive, so 
detection of CMV by PCR alone is 
insufficient for the diagnosis of 
CMV GI disease  
• Studies should give information 
regarding the presence or 
absence of GI GVHD in HSCT 
recipients.  
 
Hepatitis  Abnormal liver function tests  
AND  
CMV documented in tissue by 
histopathology, IHC, virus isolation, 
rapid culture, or DNA hybridization 
techniques  
AND  
Absence of other documented cause 
of hepatitis, including DILI  • Studies should give information 
regarding the presence or 
absence of hepati c GVHD in 
HSCT recipients.  
 
CNS  CNS symptoms  
AND  
Detection of CMV in CNS tissue by 
virus isolation, rapid culture, IHC, in 
situ hybridization, or (preferably) 
quantitative PCR.  
 • Probable disease requires CNS 
symptoms plus detection of CMV 
in CSF without visible 
contamination of blood plus 
abnormal imaging results or 
evidence of encephalitis on 
electroencephalography.  
 
Retinitis  Typical ophthalmological signs 
judged by an ophthalmologist 
experienced with the diagnosis of 
CMV retinitis  
OR 
CMV docum ented in vitreous fluid by 
NAT (for example PCR)   
Nephritis  Renal dysfunction  
AND  
Detection of CMV by virus isolation, 
rapid culture, IHS, or in situ  
hybridization in a kidney biopsy 
specimen  
AND  
Identification of histologic features of 
CMV infection  • The detection of CMV in urine by 
PCR or culture is not sufficient for 
the diagnosis of CMV nephritis as 
asymptomatic viral shedding in 
urine is common.  
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 56 of 57 
 Cystitis  Signs/symptoms of cystitis  
AND  
Detection of CMV by virus isolation, 
rapid culture, I HC, or in situ  
hybridization in a bladder biopsy 
specimen  
AND  
Histologic features of CMV infection.  • The detection of CMV in urine by 
PCR or culture is not sufficient for 
the diagnosis of CMV cystitis  as 
asymptomatic viral shedding in 
urine is common.  
Myocarditis  Signs/symptoms of myocarditis  
AND  
Detection of CMV by virus isolation, 
rapid culture, IHC, or in situ  
hybridization in a myocardial biopsy 
specimen  
AND  
Histologic features of CMV infection.   
Pancreatitis  Signs/symptoms of myocarditis  
AND  
Dete ction of CMV by virus isolation, 
rapid culture, IHC, or in situ  
hybridization in a pancreatic biopsy 
specimen  
AND  
Histologic features of CMV infection.   
Other  Presence of compatible symptoms in 
other organs  
AND  
Detection of CMV by virus isolation, 
rapid culture, IHC, or in situ  
hybridization in a biopsy specimen   
Reference [71]. BAL= bronchoalveolar lavage; CMV = cy tomegalovirus; CNS = central 
nervous system; DILI = drug induced liver injury; GI = gastrointestinal; GVHD = graft versus 
host disease; HSCT = hematopoietic stem cell transplant; IHC = immunohistochemistry; NAT 
= nucleic acid testing; PCR = polymerase chai n reaction  
 1270  
12.2 Eastern Cooperative Oncology Group  Performance Status Scale  1271  
ECOG  Description  
0  Asymptomatic (Fully active, able to carry on all predisease activities without 
restriction)  
1 Symptomatic but completely ambulatory (Restricted in physically strenuous 
activity but ambulatory and able to carry out work of a light or sedentary nature. 
For example, light housework, office work)  
2 Symptomatic, <50% in bed during the day (Ambulatory and capable of all self-
care but unable to carry out a ny work activities. Up and about more than 50% of 
waking hours)  
3 Symptomatic, >50% in bed, but not bedbound (Capable of only limited self -care, 
confined to bed or chair 50% or more of waking hours)  
4 Bedbound (Completely disabled. Cannot carry on any se lf-care. Totally confined 
to bed or chair)  
Protocol: OSU -19289  
Version Date: 09June2022  
IRB Approved:  23Feb2023  
Page 57 of 57 
 5 Death  
 1272  
12.3 Child -Pugh Classification of liver disease  1273  
 Scoring by Anomaly  
Signs or symptom  1 point  2 points  3 points  
Hepatic encephalopathy1 Absent  Grade 1 or 2  Grade 3 or 4  
Ascites  Absent  Mild Moderate  
Bilirubin (μmol/L)  < 2 mg/ dL 2 – 3 mg/dL  > 3 mg/dL  
Albumin (g/dL)  > 3.5 g/dL  2.8 – 3.5 g/dL  < 2.8 g/dL  
Prothrombin time (INR)  < 1.7  1.7 – 2.3 > 2.3  
1Hepatic encephalopathy grading:  
Grade 1: Altered mood/confusion  
Grade 2: Inappropriate behavior, impending stupor, somnolence  
Grade 3: Markedly confused, stuporous but arousable  
Grade 4: Comatose/unresponsive  
 1274  
Child -Pugh Score interpretation  
5-6 points  Child -Pugh Stage A (mild hepatic insufficiency)  
 Child -Pugh Stage B (moderate hepatic insufficiency*)  
 Child -Pugh Stage C (severe hepatic insufficiency)  
*If hypoalbuminemia is the only abnormality noted, the subject will need to have a score of ≥7 
to qualify for moderate hepatic insufficiency for this study  
 1275  